Quality Use of Medicines and Pharmacy Research Centre | UniSA

Handbook of tools to support medicine management in multimorbidity and polypharmacy



Prepared for the

Australian Government, Department of Health and Aged Care

This report was written by

Professor Libby Roughead

Dr Imaina Widagdo

Dr Anna Kemp-Casey

Quality Use of Medicines and Pharmacy Research Centre

University of South Australia GPO Box 2471 Adelaide SA 5001 www.unisa.edu.au

Acknowledgements

We are grateful for the assistance of Professor Sarah Hilmer, Professor Johnson George, Dr Emily Reeve, Ms Deidre Criddle, Assoc Prof Janet Sluggett, Dr Amy Page, and Dr Kate Wang for reviewing sections of this document.

Disclaimer

The tools in this handbook have been provided for information and education. Nothing contained in this handbook is intended to be used as medical advice and it is not intended to be used to diagnose, treat, cure or prevent any disease, nor should it be used for therapeutic purposes or as a substitute for health professional advice. The inclusion of tools in this report is for information and education purposes only, it does not represent endorsement of use. Tools developed for international audiences require consideration of Australian sources of objective information about medicines to ensure relevance to and appropriateness for the Australian health system.







Introduction	5
Tools supporting medication regimen simplicity	6
Medication Regimen Complexity Index	6
Medication Regimen Simplification Guide for Residential Aged Care (MRS GRACE)	8
Self-report questionnaires supporting medication	
adherence assessment	10
Brief Medication Questionnaire	10
Measure of Drug Self-Management	11
Morisky Medication Adherence Scale	13
Tools supporting appropriate selection of medicines	15
Medication Appropriateness Index	15
Potentially Inappropriate Medicines Lists	16
List of Australian potentially inappropriate medicines	16
Beers Criteria	18
STOPP/START	18
Fit for the Aged (FORTA)	19
MEDSTOPPER	20
Tools to assist identification of cumulative toxicity	21
Drug Burden Index	21
Anticholinergic burden calculator	22
Falls risk medicines	23
Scottish Polypharmacy Guidance: Cumulative Toxicity tool and adverse	
drug reactions (ADR)	24
Medichec	25
Tools supporting symptom assessment for adverse	77
Patient Reported Outcome Measure Inquiry into Side-Effects (PROMISE)	27
PHASE 20 and Phase PROXY	29
Tools to identify people at risk of Medicine Related Problems	30
Self-Medication Risk Assessment Instrument	30
Medication risk checklist for older adults (LOTTA)	32
PHarmacie-R	32





Tools to support identification of patients suitable for deprescribing 35 Patient Attitudes Towards Deprescribing questionnaire 35 Tools to support medication switching and tapering 36 Medicine switching calculators 38 Medicine tapering calculators 38 References 41 Appendix 1: Australian Potentially Inappropriate Medicines List⁵⁶ 47



Multimorbidity, the presence of more than one chronic illness, is common, with an estimated 50% of persons 65 years and over living with more than one chronic condition.¹ Alongside the increase in multimorbidity has been a rise in use of medicines concurrently.^{2, 3} When a person is taking five or more medicines concurrently this is frequently referred to as polypharmacy.⁴ High levels of concurrent use of medicines, while very often necessary, also has the potential to result in increased risk of harm, including adverse medicine events, hospital admissions due to medicines and, sometimes, death.5-9 Australian evidence estimates that up to one-third of unplanned hospital admissions in persons 65 years and over are due to problems with their medicines.¹⁰

There are a number of tools now available to support health professionals manage concurrent use of medicines and reduce the risk of harm. This handbook collates examples of these tools across the spectrum of factors where problems with medicine use can develop.

The handbook includes tools designed to:

- reduce medicine regimen complexity;
- identify non-adherence;
- identify medicines that are considered generally inappropriate in older people;
- identify medicines that may have been omitted but are considered beneficial in older people;
- detect medicine related side effects;
- identify the potential for harms due to the cumulative effects of medicine use;
- support cessation of medicines; and
- support medication switching and tapering.

The handbook includes at least one tool for each of these areas and, wherever possible, tools developed for Australian practice are included. Tools from other health jurisdictions have also been included but should be used with caution as medicines available in other jurisdictions may not be available in Australia or may be available in different strengths or formulations. There may be medicines available in Australia that are not available in other jurisdictions and so these medicines may not appear in the international tools described. Thus, Australian sources of objective information would always need to be consulted when using tools developed for other jurisdictions. We limited inclusion to tools developed by health departments, professional societies, academic institutions or identifiable health professionals. Tools where the development process or developer could not be identified were excluded. Tools that were disease specific were excluded, as were tools that relied on simulated medication regimens. The handbook is not an exhaustive list of all tools. The tools in this handbook are intended for education and information and are not intended as a substitute for independent professional assessment and advice.





As the number of medicines taken by a person increases, so too does the potential for the medicine regimen to become more complex. Complex medicine regimens arise due to people having to take medicines at different times of day, or due to trying to follow different instructions about when or how to take the medicine; such as before, with or after food. Complex medicine regimens are not intentional and usually arise incidentally as, over time, new medicines are added to an individual's regimen. Not surprisingly, when someone is on multiple medicines, the daily regimen can become so complex that it can be difficult for people to adhere to the regimen. There is significant evidence showing complex medication regimens are a risk factor for medication non-adherence,¹¹ which can subsequently result in loss of disease control and increased morbidity. There is also evidence that, for many people, it is possible to simplify the medicine regimen to reduce this risk¹² and improve health outcomes.¹³ For older people taking medicines at least twice daily between 50% and 70% may be able to take their medicines in a simpler way.¹⁴ In this section of the handbook we provide details of Australian tools designed to support medication regimen simplification.

Medication Regimen Complexity Index

Purpose

To assist health practitioners to identify the complexity of a medication regimen.

Description

An explicit tool comprising three sections covering dosage form, directions for use, and additional directions.¹⁵ Within each section are items corresponding to type of dosage form, frequency of directions, and complexity of additional directions. These factors are weighted according to health professional assessment of their difficulty of use or difficultly to understand or follow. The index is applied to prescribed medicines only. Scores are totalled for each section, and the final complexity index is the sum of the three sections. Higher scores indicate higher complexity. The tool is available as an appendix to the publication¹⁵ at: journals.sagepub.com/doi/10.1345/aph.1D479

The tool has also been successfully adapted to enable automated use in electronic health records in the US,¹⁶⁻¹⁸ with the matching algorithms available for download for non-commercial use on the referenced website or in the supplementary data to the paper.

Setting

Applicable across all health settings.

Audience

Suitable for use by all health practitioners.

Method of development

The index, developed in Australia, was based on factors known to influence medication complexity, including the number of medications, the dosage frequency, dosage form, and the instructions for use.¹⁵ It was pilot tested on hypothetical medicine regimens, and refined, before further piloting on 134 actual medication regimens. After further refinement the index was reviewed by eight pharmacy researchers. The tool was then applied to 50 medication regimens selected from the original 134 and ranked according to complexity. Six regimens selected from across the range of complexity were extracted and independently ranked for complexity by a five member expert panel. Studies examining a cut-off for the index, suggest high complexity is indicated by scores above cut-offs varying from 11.5 to 25 for older adults; the variation in the cut-off is dependent on the criteria for establishing the cut-off.19, 20

Advantages

The index has been tested for criterion validity, construct validity and reliability. The tool has been used widely in the research setting, with increasing complexity found to correlate with poorer adherence, hospital readmission, and adverse medicine events.²¹ The tool is available in multiple languages.²²⁻²⁵



Limitations

The tool does not account for non-medication factors, such as patient factors (e.g. cognitive or physical impairment) which may also contribute to people finding regimens complex to follow.

Data required

Medication chart.

Example

The following is an example of application of the medication regimen complexity index. Note the variation in scores is due to weights for different formulations or directions. A spray formulation is weighted more highly than tablets, hence the two-rating compared to one for tablets. More frequent dosing is weighted more highly, and additional directions are scored.

Medication Regimen	Dosage Form	Dosing Frequency	Additional Directions
Diclofenac 50 mg tablets twice a day with food as needed	1	2	1
Apixaban 5 mg tablet twice a day	1	2	
Rosuvastatin 10 mg tablet daily	1	1	
Pantoprazole 40 mg tablets daily	1	1	
Citalopram 20 mg tablet daily	1	1	
Oxazepam 15 mg tablet before bed as needed	1	0.5	1
Atenolol 25 mg tablet twice a day	1	2	
Amlodipine 5 mg tablet daily	1	1	
Oxybutynin 5mg tablet twice a day	1	2	
Glyceryl trinitrate (GTN) spray use as directed for chest pain	2		2
Totals	11	12.5	4
Final Score	27.5		



Medication regimen simplification guide for residential aged care (MRS GRACE)

Purpose

To assist health practitioners to simplify medication regimens by reducing the number of administration times required per day.

Description

An implicit tool comprising the following five questions:

Consideration can be given to administering all medications at the same time each day unless the following apply:

- 1. Is there a resident related factor that precludes simplification?
- 2. Is there a regulatory or safety imperative that precludes simplification?
- Is simplification likely to result in any clinically significant drug– drug, drug–food, or drug–time interactions?
- 4. Is there no alternative formulation available that can support less complex dosing?
- Is simplification likely to result in any unintended consequences for the resident or facility?²⁶

When using the tool, practitioners generally start by obtaining a complete medication history and then considering whether any medicines could be ceased. Practitioners then review the remaining necessary medicines and consider if the medication regimen can be simplified. Simplification may involve reducing the number of medicine administration times, either by shifting the time of administration or using alternative preparations. The tool is designed to be used within a person centred approach as part of a comprehensive medicines review or as a stand-alone activity; with the person whose regimen is under review actively engaged in the process.

Setting

Initially developed for the aged-care setting, but suitable for all health settings.

Audience

Suitable for use by pharmacists, doctors, geriatricians.

Method of development

An expert panel comprising both health practitioners and consumers identified factors to consider that may assist with simplifying a medicine regimen. The nominal group technique used to obtain the final list of factors to consider. Two pharmacists independently applied the tool to the same medicine regimens for a sample of 50 people who had at least two medication administration times a day. The results showed the majority of regimens could be simplified, and that there was fair agreement between pharmacists (Cohen's kappa=0.38±0.13, 95% CI 0.12-0.64).²⁶ The tool has also been validated among general practitioners and geriatricians.14

Advantages

A simple tool for use in practice to guide medication regimen simplicity. It has been shown to be effective in reducing the number of medication administration times per day.¹⁴ It has been demonstrated to reduce medication incidents²⁷ and results in a sustained reduction in medication administration times at 12 months.²⁸ In settings where other people are involved in medicine administration, simplification of regimens can also free up staff time enabling staff to be engaged in other activities.

Limitations

The implicit nature of the tool results in variation in how regimens are simplified which is dependent on the user.

Data required

Medication administration chart or best possible medication history with medication administration times recorded.



Example

An example of a hypothetical medication regimen before and after simplification appears below. In this hypothetical example, the best possible medication history would be taken first. If simpler regimens were possible, then the person whose medicine was under review would be consulted and would need to agree to implement the suggested changes. A plan for follow up with the person post-simplification would be put in place to determine any issues with the revised regimen.

Time-point	Current Media	catio	ons	Total number of administration times	Total number of tablets taken per day	
	Medication name, dose and instructions	•	Time(s) administered	per day for regular medications		
Before simplification	 Aspirin 100mg daily Metformin 500mg twice daily Irbesartan 150mg daily Atorvastatin 40mg daily Pantoprazole 40mg daily Docusate and senna tablets when needed 	\rightarrow \rightarrow \rightarrow \rightarrow \rightarrow \rightarrow	0800 0800, 1800 0800 2100 0800 once weekly	3	6	
After simplification	 Aspirin 100mg daily Metformin 1000mg controlled release once daily Irbesartan 150mg daily Atorvastatin 40mg daily Pantoprazole 40mg daily Docusate and senna tablets when needed 	$\begin{array}{c} \uparrow \\ \uparrow $	0800 0800 0800 0800 0800 Takes approx. once weekly	1	5	

Source

Creator Janet Sluggett, adapted from 'Hypothetical medication regimen illustrating a reduction in the number of medication administration times for regular medications at follow-up,²⁹ available under CC BY-NC³⁰ at bmjopen.bmj.com/content/9/7/e025345.info

Self-report questionnaires supporting medication adherence assessment

A subset of patients experience difficultly adhering to the medication regimen. There may be many reasons for this, including the complexity of the medication regimen, patient related factors such as beliefs about the benefits or harms of medicines, cognitive factors such as cognitive impairment, or physical factors that limit the ability to open containers or use devices, as well as medicine related factors such as taste or the side effects. Tools have been developed for health practitioners to identify patients with adherence problems. While there are digital tools such as electronic pill bottles, patient self-report tools are a simple option for identifying patients who may need support to achieve medication adherence. There are at least 27 self-report tools that have been used in the research setting with variability in their ability to accurately detect nonadherence.^{31, 32} Many have been developed for specific diseases, while some may have limited application in clinical practice due to the number of questions they asked and length of time to complete.

In this section of the report, we describe three validated self-report tools with less than twelve questions for identifying adherence to medicines. Additional tools have been reported in overviews to medication adherence measures in the published literature.³³

Brief medication questionnaire

Purpose

Structured self-report measure to assess medication adherence.

Description

The Brief Medication Questionnaire includes nine questions;³⁴ five focused on a person's medication taking behaviour in the last week (regimen questions), two focused on the person's beliefs about the medicines (how well the medicine works or if it bothers them) and one question focused on whether the person has difficulty remembering to take their medicines, the answer to which is considered in relation to how many times per day the person takes the medicine.

A copy of the tool is available at:35

pharmacy.wisc.edu/wp-content/ uploads/2016/05/BMQ-H-9_ website2022.pdf

*Copyright belongs to the author, but the questionnaire is available for non-commercial purposes with proper acknowledgement.

Setting

Primary care.

Audience

People taking medicines.

Method of development

The questions about medication regimen were found to have high predictive ability (100%) and accuracy (95%) to detect repeat non-adherence, but not for sporadic non-adherence (missing the occasional dose). The questions related to difficulties remembering to take one's medicines were found to have high sensitivity (90%) and accuracy (85%) to identify sporadic non-adherence.

Advantages

Simple to use self-report tool.

Limitations

May not detect all cases of non-adherence. Has been predominantly used for adherence with cardiovascular medicines.

Data required

Interview: patient self-report.

Example

A copy of the survey appears on the next page.

Question	Answer								
In the past week, did you take any of this [medicine]?	Yes / No								
How many days did you take this [medicine]?	l took it:	0	1	2	3 da	4 ays	5	6	7
How many times a day did you usually take it?	l took it:			0	1 times	2 a day	3		
How much did you usually take each time?	l took it:	0 pi	lls	½ pill	ا 1 each	oill time	2 pills	3	pills
How many times did you MISS taking it?	I missed it:	0	1	2	3 tin	4 nes	5	6	7
How well does this [medicine] work for you?		Not at	all well	Moderate	ely well	Very	/ well	Don't	know
How much does this [medicine] bother you?		Not	at all	Bothers	a little	Bothe	rs a lot	Don't	know
How much difficulty are you having: It is hard to remember all the doses?			None		A li	ttle		A lot	

© 2006-2022 B.L. Svarstad, Ph.D. (University of Wisconsin System). All rights reserved.

Measure of drug self-management

Purpose

Structured questionnaire to assess medication adherence.

Description

The Measure of Drug Self-Management³⁶ is a 12 item tool that asks questions about adherence but also includes questions relate to costs as well as a person's attitudes towards medicines. The questions are scored and can be summed with higher scores indicating better medication management.

Setting All health settings.

Audience People taking medicines.

Method of development

The measure was developed based on an initial set of 67 questions, both subjective and objective, that had been created after a review of the literature and existing tools and the input of experts, followed by review by physicians, patients and persons expert in information technology, the latter for consideration of deployment in electronic health records.³⁶ The initial set of questions was tested among a group of 193 people recruited from a medical clinic, with items tested by factor analysis, tested for internal consistency and correlated against existing medication adherence scales and clinical measures, with redundant questions eliminated to create the final scale. The scores can be summed, with higher scores indicating better self-management.



Advantages

Simple to use patient interview tool, that includes assessment of beliefs or attitudes as well as adherence. In the population with diabetes and hypertension in which the measure was tested, lower scores correlated with poorer clinical measures for blood pressure and low-density lipoprotein (LDL) cholesterol, with a trend also for glycosylated haemoglobin (HbA1c).

Limitations

May not detect all cases of non-adherence.

Data required

Patient interview.

We would like to ask you a few questions to make sure you are taking your medicine safely. The first two questions are about specific medications that you may be taking.						
1. Did you forget to take your (insert drug 1 name) at any time last week?						
Yes	0					
No	1					
l do not know	0					
2. In the past month, have you stopped taking (insert drug 2 name) for any reason without t	celling your doctor?					
Yes	0					
No	1					
l do not know	0					
For the next set of questions, please tell us how often the following statements are true fo	r you.					
3. I often forget to take my medicine.						
Never	1					
Some of the time	0					
Most of the time	0					
All of the time	0					
4. I am organized about when and how I take my medicines.						
Never	0					
Some of the time	0					
Most of the time	0					
All of the time	1					
5. I have a hard time paying for my medicines						
Never	1					
Some of the time	0					
Most of the time	0					
All of the time	0					
For the last set of questions, please tell us if you agree or disagree with the following state	ements.					
6. The print instructions on my prescription bottles are confusing.						
Agree	0					
Disagree	1					



7. Having to take medicines worries me.	
Agree	0
Disagree	1
8. I often have a hard time remembering if I have already taken my medicine.	
Agree	0
Disagree	1
9. I do not take my medicines when I am feeling sad or upset.	
Agree	0
Disagree	1
10. My medicines disrupt my life.	
10. My medicines disrupt my life. Agree	0
10. My medicines disrupt my life. Agree Disagree	0
10. My medicines disrupt my life. Agree Disagree 11. When my medicine causes minor side effects, I stop taking it.	0 1
10. My medicines disrupt my life. Agree Disagree 11. When my medicine causes minor side effects, I stop taking it. Agree	0 1 0
10. My medicines disrupt my life. Agree Disagree 11. When my medicine causes minor side effects, I stop taking it. Agree Disagree	0 1 0 1
10. My medicines disrupt my life. Agree Disagree 11. When my medicine causes minor side effects, I stop taking it. Agree Disagree 12. The idea of taking medications for the rest of my life makes me very uncomfortable.	0 1 0 1
10. My medicines disrupt my life. Agree Disagree 11. When my medicine causes minor side effects, I stop taking it. Agree Disagree 12. The idea of taking medications for the rest of my life makes me very uncomfortable. Agree	0 1 0 1 0

Source

Measure of Drug Self-Management. Created by Bailey SC, Annis IE, Reuland DS, Locklear AD, Sleath BL, Wolf MS.³⁶ Available for non-commercial use under CC BY-NC 3.0³⁷ at: pmc.ncbi.nlm.nih.gov/articles/PMC4527367/#SD1-ppa-9-1101

Morisky Medication Adherence Scale

Purpose

Structured self-report questionnaire to assess medication adherence.

Description

This tool requires a paid licence to use. There are two versions of the scale; one comprising four questions the other comprising eight questions.³⁸

The Morisky Medication Adherence Scale-4 (MMAS-4):

- 1. Do you ever forget to take your medication?
- Do you ever have problems remembering to take your medication?
- When you feel better, do you sometimes stop taking your medication?
- Sometimes if you feel worse when you take your medication, do you stop taking it?

The Morisky Medication Adherence Scale-8 (MMAS-8):

- 5. Do you sometimes forget to take your medication?
- 6. People sometimes forget to take their medications for reasons other than forgetting. Thinking over the past two weeks, were there any days when you did not take your medication?
- 7. Have you ever cut back or stopped taking your medication without telling your doctor, because you felt worse when you took it?
- 8. When you travel or leave home, do you sometimes forget to bring your medication?
- Did you take your medication the last time you were supposed to take it?
- **10.** When you feel like your symptoms are under control, do you sometimes stop taking your medication?
- Taking medication every day is a real inconvenience for some people. Do you ever feel hassled about sticking to your treatment plan?
- 12. How often do you have difficulty remembering to take all your medications?

It is available for use under licence

Permission to use the Morisky Scales is granted by obtaining a license. The Morisky Scales are protected by US copyright laws and may not be modified, sold, translated into another language or adapted for another medium (e.g. smartphone, tablet, computer, or internet) without a license.³⁸

Setting

Primary care.

Audience

People taking medicines.

Method of development

The original four item scale was derived from earlier research utilising five questions measuring medication taking behaviour, with the rationale that reasons for omission of medicines could be related to forgetting to take medicines, ceasing the medicine because a person was feeling better or starting the medicine because a person was feeling worse, or carelessness.³⁹ The MMAS-8 contains an additional four times, which were added to account for circumstances contributing to adherence behaviour.^{40, 41} The scale has been tested for validity and reliability with significant heterogeneity in results but acceptable internal consistency and reliability for diseases including diabetes and osteoporosis.42,43

Advantages

Simple to use self-report tool.

Limitations

May not detect all cases of non-adherence. It is only available under licence.

Data required

Interview: self-report.

Tools supporting appropriate selection of medicines

Medication appropriateness index

Purpose

Designed to identify the appropriateness of medicine use.

Description

The Medication Appropriateness Index⁴⁴ first developed in 1992, includes ten implicit criteria presented as questions: is there an indication for use? Is the medication effective for the condition? Is the dosage correct? Are the directions correct? Are the directions practical? Are there clinically significant medicine-medicine interactions? Are there clinically significant medicine-disease interactions? Is there unnecessary duplication with other medicines? Is the duration of therapy acceptable? Is this medicine the least expensive alternative compared to others of equal utility? Each criteria is scored on a scale ranging from A – appropriate, B – marginally appropriate, C - inappropriate. Criteria are also weighted, with higher weights related to indication and effectiveness, and lowest weights related to the practicality of directions, duplication, duration, expense.⁴⁵ A summed appropriateness score can be generated for each medicine and an overall score for each person. A higher score is indicative of more appropriate medicine use.

A three item version of the tool is also available. The three item version includes items related to indication, effectiveness and duplication.⁴⁶

A copy of the ten item and three item tool⁴⁶ is available at: <u>karger.com/pps/</u> <u>article/91/2/78/826542/The-Medication-</u> <u>Appropriateness-Index-A-Clinimetric</u>

Setting

Applicable across all health settings.

Audience

Health professionals.

Method of development

The index was developed based on a literature review and expert opinion of important criteria related to medicine appropriateness.⁴⁴ The initial criteria were piloted as a five point Likert scale, then modified to the 3 point scale. It was then tested for reliability among 10 older persons taking five or more medicines, and found to have good inter and intra-rater reliability.⁴⁴ A subsequent study assessed content validity and developed weighting for each criteria.⁴⁵

Advantages

The tool covers the breadth of criteria considered important for assessing the appropriateness of medicine use.⁴⁵ The tool has been widely used in research with the majority of studies in which it has been assessed finding the tool has acceptable inter- and intra- rater reliability.⁴⁷ The use of the index has been compared to use of explicit criteria lists, with the Medication Appropriateness Index detecting more prescribing problems that explicit criteria lists.⁴⁷ This is most likely because the Index is applied to all the medicines a person is taking, while the explicit criteria only apply to a subset of the medicines a person may be taking.

Limitations

The ten item tool is time consuming to administer, with ten questions to be considered for each medicine.

Data required

Medication history, Medical record.

Potentially inappropriate medicines lists

Lists of explicit criteria to identify potentially inappropriate use of medicines have been developed by a number of groups in an effort to reduce inappropriate medicine use.48,49 The explicit criteria are generally negative lists, meaning the lists identify medicines that should not be used in a given population, or are specific to doses or conditions in which the medicine should not be used. The majority apply to older adults (aged 65 years or more) with some applying to frail populations. Positive and negative lists have also been developed. Positive lists identify medicines that should generally be given in the specified population (the positive list) and are designed to detect omissions of necessary therapy.

Despite the availability of many lists,⁴⁸ there is significant heterogeneity or variability in the medicines or criteria included in different lists across the world. This is largely due to availability of medicines and differences in expert opinion, as the majority of the lists represent consensus lists based on expert opinion after a review of the evidence. Despite the differences in content, there is considerable evidence demonstrating that older people taking the medicines on these lists are at increased risk of harm^{50, 52} and that the use of potentially inappropriate medicines results in significant costs to the health system.^{52, 53} Randomised controlled trial evidence supports the use of these lists in practice, with the evidence showing that they reduce the use of potentially inappropriate medicines and reduce adverse medicine events.^{54, 55} The lists are intended to aid health practitioners in identifying potentially inappropriate medicines only and do not take account of all patient circumstances that may be relevant to decision making. When considering each individual, there may be medicines a person is taking that are not included on the lists but which are still inappropriate for some people, while there also may be instances where medicines on the lists are maintained at the discretion of the treating practitioner.

List of Australian potentially inappropriate medicines

Purpose

Designed to identify medicines that should not be used in older people.

Description

Explicit criteria identifying medicines that are potentially inappropriate in the Australian population.⁵⁶ The final list includes 19 medicines or medicine classes. For sixteen of these medicines or classes, there was at least one medicine for which there was consensus agreement that it be avoided in all older people. For the remaining three classes, the medicines were considered best avoided in specific conditions. The full list is available online at: <u>onlinelibrary.wiley.com/doi/10.1111/</u> imj.16322

A copy of the list⁵⁶ is provided in Appendix A

Setting

Applicable across all health settings.

Audience

Health professionals.

Method of development

The initial list of medicines was created after a review of existing published lists including explicit criteria of potentially inappropriate medicine use in older people. The final list was developed after a two round Delphi method involving at least 32 experts in each round.⁵⁶ Acceptance of the final criteria required at least 75% of reviewers to have high levels of agreement with the criteria.

Advantages

Published in 2024 the list is current and only includes medicines on the Australian market.

Limitations

The lists are intended to aid health practitioners in identifying potentially inappropriate medicines only and do not take account of all patient circumstances.



When considering each individual, there may be medicines a person is taking that are not included on the lists but which are still inappropriate for some people, while there also may be instances where medicines on the lists are maintained at the discretion of the treating practitioner.

Data required

Medication chart, medical history.

Example

The example below shows a medicine regimen and its comparison with the recommendations in the Australian potentially inappropriate list.

Current Medicine Regimen	Should this medicine be avoided in older people? ⁵⁶	Should this medicine be avoided in older people with specified conditions? ⁵⁶	Instead of prescribing this medicine or class of medicines for older people, consider these alternatives: ⁵⁶	
Diclofenac 50 mg twice a day as needed	Yes, listed on Australian potentially inappropriate medicine list	Yes, to be avoided if the patient has: history of gastrointestinal bleeding, increased bleeding risks, frailty, poor renal function, peptic ulcer disease, multimorbidity, chronic kidney disease, heart failure, cardiovascular diseases	Paracetamol	
Apixaban 5 mg twice a day	No	Yes, to be avoided if the patient has: peptic ulcer disease, increased bleeding risk, risk of falls, multimorbidity, polypharmacy, poor renal function, chronic kidney disease	N/A	
Rosuvastatin 10 mg daily	Not on list	N/A	N/A	
Pantoprazole 40 mg daily	Not on list	N/A	N/A	
Citalopram 20 mg daily	Not on list	N/A	N/A	
Oxazepam 15 mg before bed as needed	No	Yes, to be avoided if the patient has: a history of falls, other medications with sedative properties, polypharmacy, frailty, neurodegenerative diseases (e.g. delirium), dependency, renal impairment, long-term use	Melatonin (for indication of sleep), nonpharmacological strategies (e.g. yoga)	



Beers Criteria

Purpose

Designed to identify medicines that should not be used in older people.

Description

Explicit criteria highlighting medicines that are not recommended to be used in older people, or not recommended to be used in older people with certain conditions or at certain dosages. This US List was first developed in 1991 for aged-care residents. Later versions encompassed both older community dwelling persons and aged-care residents (i.e. all persons 65 years and older). The criteria are maintained by the American Geriatric Society and the term AGS Beers Criteria® is a registered trademark.⁵⁷ The list has been adapted and applied in the Australian setting.^{58, 59} The full list is available⁵⁷ at: agsjournals. onlinelibrary.wiley.com/doi/10.1111/jgs.18372

Setting

Applicable across all health settings.

Audience

Health professionals.

Method of development

Developed by a two round Delphi method.⁴⁰ Acceptance of the final criteria required at least 75% of reviewers to have high levels of agreement with the criteria. The list was most recently updated in 2023 by an expert panel after evidence review.⁵⁷

Advantages

Regularly updated by the US American Geriatric Society.

Limitations

The criteria are based on medicines marketed in USA and needs to be adapted for Australia.⁴⁸ The list is limited to medicines and does not account for individual preferences. The list is intended to aid health practitioners in identifying potentially inappropriate medicines only and does not take account of all patient circumstances. When considering each individual, there may be medicines a person is taking that are not included on the lists but which are still inappropriate for some people, while there also may be instances where medicines on the lists are maintained at the discretion of the treating practitioner.

Data required

Medication chart, medical history.

Example

To use the AGS Beers Criteria®, the medication history is compared to the criteria in the same way as the example presented under the list of Australian potentially inappropriate medicines.

STOPP/START

Purpose

Designed to identify medicines that should not be used in older people (the STOPP criteria) and identify medicine omissions in older people (the START criteria). There is also a version of STOPP criteria for frail older people (STOPPFrail).^{60, 61}

Description

The STOPP START criteria was first published in 2008, with updates in 2015 and 2023.^{60,} ⁶¹ The current version includes 133 criteria related to STOPP and 57 criteria related to START. The STOPP/START criteria have been recommended for use as part of medication reviews by the UK National Institute of Health and Clinical Excellence, the British National Formulary and the UK Royal College of General Practitioners and British Geriatrics Society.

The STOPP START criteria are available as a supplementary file to the published paper^{60, 61} at: <u>static-content.springer.com/esm/art%3A</u> 10.1007%2Fs41999-023-00777-y/Media Objects/41999_2023_777_MOESM1_ESM.pdf

STOPPFrail was first published in 2017 and identifies medicines that can be ceased or reduced in frail older persons with limited life expectancy. It includes 27 criteria related to medicines that could be ceased in the frail population.⁶² An updated version (Version 2), revised to 25 criteria was published in 2021.⁶³ Examples of the criteria include: 1) to cease lipid lowering therapy, and 2) to reduce blood pressure medicine or discontinue it in persons with a systolic blood pressure persistently



below 130mmHg. Version 2 also includes three criteria, all of which must be met, to identify the people for whom STOPPFrail is intended.⁶³

The STOPPFrail criteria are included in the published paper⁶³ available at: <u>academic.oup.</u> <u>com/ageing/article/46/4/600/2948308</u>

Setting

Applicable across all health settings.

Audience

Health professionals.

Method of development

The most recent version of STOPP/START was developed using a four round Delphi method involving 11 physicians with expertise in geriatric pharmacotherapy after reviewing the previous version, reviewing changes in treatment guidelines and undertaking a review of the published literature. Acceptance of the final criteria required at least 75% of reviewers to have high levels of agreement with the criteria.^{60, 61} A similar method was employed for STOPPFrail.⁶³

Advantages

Randomised controlled trial evidence supports the effectiveness of using lists such as the STOPP/START criteria in practice to reduce inappropriate medicine use.^{54, 55, 64} The STOPPFrail list has been shown in randomised controlled trials to reduce medicine use and costs.⁶⁵ The trial was too small to assess the impact on health outcomes.

Limitations

The criteria are based on medicines marketed in Europe and may need to be adapted for Australia.⁴⁸ The lists are intended to aid health practitioners in identifying potentially inappropriate medicines or medicines that may have been omitted and do not take account of all patient circumstances. When considering each individual, there may be medicines a person is taking that are not included on the lists but which are still inappropriate for some people, while there also may be instances where medicines on the lists are maintained at the discretion of the treating practitioner.

Data required

Medication chart and medical, personal care history. STOPPFrail requires the opinion of caring physician with regard to patient lifeexpectancy.

Example

To use the criteria, the medication history is compared to the STOPP/START criteria in a similar way as the example presented under the list of Australian potentially inappropriate medicines.

Fit for the Aged (FORTA)

Purpose

To identify medicines that are beneficial in older people as well as those that should be used with care or should not be used at all.

Description

Fit for the Aged (FORTA) represents another list of explicit criteria to support appropriate use of medicines in older people. It has four categories of medicines: A (A-bsolutely), B (B-eneficial), C (C-areful), and D (D-on't).66 Medicines in the absolutely category are considered both efficacious and safe for the recommended indication. Medicines in the beneficial category are considered effective but may have safety concerns. Medicines in the careful category have equivocal efficacy or safety concerns, while medicines in the don't category should not be used at all. Current versions of FORTA are Version 4,66 EURO-FORTA Version 267 and US-FORTA.68 Forta version 4 contains 299 medicines or medicine groups covering 30 indications.

Setting

Applicable across all health settings.

Audience

Health professionals.

Method of development

The original list, published in 2008,⁴⁰ was created as an author generated list. It was subsequently validated by experts from Germany and Austria using a 2 round Delphi process in 2012.⁶⁹ In 2018, adaptation of the original list was extended across Europe,



with 47 experts involve in a two round Delphi Process. Acceptance of the final criteria required at least 75% of reviewers to have high levels of agreement with the criteria. The outcome included seven country specific lists and an overarching Euro-FORTA list.^{69, 70} Lists have also been adapted for other countries.

Advantages

Randomised controlled trial evidence in hospital patients has shown that implementation of the list does reduce medicine use and is associated with less adverse medicine events.⁷¹

Limitations

The criteria are based on medicines marketed in Europe and may need to be adapted for Australia.⁴⁸ The lists are intended to aid health practitioners in identifying potentially inappropriate medicines or medicines that may have been omitted and do not take account of all patient circumstances. When considering each individual, there may be medicines a person is taking that are not included on the lists but which are still inappropriate for some people, while there also may be instances where medicines on the lists are maintained at the discretion of the treating practitioner.

Data required

Requires medical chart, medication history.

Example

The medication history is compared to the FORTA criteria in a similar way as the example presented under the list of Australian potentially inappropriate medicines.

MEDSTOPPER

Purpose

Medstopper is an interactive digital tool to provide guidance about medicine cessation.

Description

The digital tool enables health professionals to enter a list of medicines the person is on to create a Medstopper plan that includes prioritisation of the medicines to consider ceasing from highest to lowest priority. The priority is based on the medicine's potential to improve symptoms or reduce future illness as well as its likelihood of harm. The tool includes information on the indication for medicine use and incorporates recommendations for frail patients. It provides information on a tapering approach, possible symptoms associated with withdrawal and links to the AGS Beers Criteria® or STOPP criteria. The tool is available⁷² at: www.medstopper.com/team.html

Method of development

The tool has been developed Canadian experts in evidence-based medicine and therapeutics in older people and is maintained by the University of British Columbia.

Setting

Applicable across all health settings.

Audience

Health professionals.

Advantages

The tool provides capacity to review the whole patient regimen and is colour coded to assist with identifying the priority for cessation.

Limitations

The tools is still in beta testing and is based on medicines available in Canada.

Data required

Medication chart, medical history.



Harm from medicines is not only related to individual medicines but can be due to interactions between medicines or the cumulative effects of medicines. A US study found that for people on five or more medicines there were three potential interactions, however, this rose significantly as the number of medicines increased, with people who took ten medicines concurrently subject to 12 potential medicine-medicine interactions.³ Where two or more medicines have the same side effects, there is higher potential for risk of harm due to the additive risk from each individual medicine.73 A number of tools have been developed to support health professionals identify potential risk of harms due to cumulative medicine use. In this section of the handbook we provide examples of tools designed to detect the sedative and anticholinergic burden of a patient's medication regimen, as well as tools that focus on medicines, the concurrent use of which, could contribute to a broader range of side effects.

Drug Burden Index

Purpose

To provide information on the cumulative burden of using one or more medicines with anticholinergic or sedative properties.

Description

The Drug Burden Index (DBI) is calculated from the medication regimen for each individual and represents the sum of doses of medicines with sedative or anticholinergic effects, standardised by the minimum daily dose as approved by the US Food and Drug Administration⁷⁴ or local drug regulator (e.g. the Therapeutic Goods Administration in Australia). The formula is presented as:



Where E is the pharmacological effect, α is a proportionality constant, D is the total daily dose used and δ is the minimum effective adult daily dose.⁷⁴ A detailed description on how to calculate the Drug Burden Index has been published.⁷⁵ A digital version of the index has been developed⁷⁶ and is incorporated into software to support medication reviews.^{76, 77} It has also been incorporated into some hospital electronic medical records to inform reviews in hospital.^{78, 79}

The software is available for use by Australian registered healthcare practitioners after registering for an account⁸⁰ at: <u>gmedss.com/about</u>

Setting

Applicable across all health settings.

Audience

Health professionals.

Method of development

The tool was first developed in 2007 based on pharmacological principles and validated against physical and cognitive function; people with higher scores have poorer physical and cognitive function.⁷⁴ Since then the tool has been widely validated internationally in clinical and pre-clinical studies.⁸¹

Advantages

The tool provides a single score for all anticholinergic and sedative medicines the person is taking, with a higher value indicating a greater burden. The tool is predictive of adverse medicine events and poor outcomes, with a higher score meaning adverse events are more likely.⁸¹ The tool has been used within medicine reviews in community, nursing home and hospital settings to support deprescribing.^{82, 83}

Limitations

The score measures risk of medication-related functional impairment, but does not provide guidance on clinical appropriateness. The score alone cannot be easily interpreted, as a number of medicines may contribute to it and it is a continuous score. Therefore, reports must include a list of contributing medicines and provide guidance that while the association



between the Drug Burden Index score and adverse outcomes is continuous, a Drug Burden Index score ≥1 is considered high risk.

Data required

Medication regimen with daily doses. If you are manually calculating the drug burden index, minimum effective daily adult doses as approved by the US Food and Drug Administration or local medicines regulator are also required.

Example

The following example provides a calculation of the Drug Burden Index for a person taking:

- Enalapril 20mg daily orally
- Oxybutynin 5mg three times a day orally
- Tramadol 50mg twice a day orally
- Citalopram 20mg night orally

The Drug Burden Index calculates as follows:

Medicine	Daily dose	Anticholinergic or sedative	Minimum effect daily adult dose*	Drug Burden
Enalapril	20mg	No	N/A	0
Oxybutynin	15mg	Yes	10mg	0.6
Tramadol	100mg	Yes	100mg	0.5
Citalopram	20mg	Yes		0.5
Total Drug Burden for person	1.6			

*calculated using data from the Australian Therapeutic Goods Administration

Anticholinergic burden calculator

Purpose

Designed to provide information on the cumulative burden of using one or more medicines with anticholinergic properties.

Description

The Anticholinergic Burden Calculator is a free online tool designed to provide information on the cumulative burden of using one or more medicines with anticholinergic properties.⁸⁴ Medicines are scored based on a scale of 1, 2 or 3, where 1 indicates weakly or possibly anticholinergic, 2 indicates moderately anticholinergic and 3 indicates highly anticholinergic. The tool is available online⁸⁴ at: www.acbcalc.com/

Method of development

There are numerous tools to identify the anticholinergic burden, with this calculator being based on an amalgamation of two scales: the anticholinergic cognitive burden scale (ACB)⁸⁶ and the German anticholinergic burden scale (GABS).⁸⁷ The tool has been created by a practicing general practitioner in the UK.⁸⁴

Setting

Applicable across all health settings.

Audience

Health professionals.

Advantages

The score is a sum of anticholinergic scores and the visual display highlights which medicines make the most contribution.



Limitations

The score does not account for the dose prescribed. The tool has been developed by a UK health practitioner and may not include all medicines available in Australia.

Data required

Medication Chart.

Example

This example provides a display of how output from the anticholinergic calculator would appear, with colouring used to highlight the medicines with the most anticholinergic effect.

Total Antichlolinergic Burden Score	High Risk 5
Medicine: Paracetamol	Score: 0
Medicine: Tramadol	Score: 2
Medicine: Amitriptyline	Score: 3

When the graphic is produced, the website text states that persons with a score of 3 or more are at higher risk of confusion, falls and death. The text includes advice suggesting review of the medicines is necessary when scores of 3 or more are present, to discuss the medicines with the patient or family members and to consider if there are alternative medicines to which the patient could be switched. The website includes a link to potential alternative medicines.

Falls risk medicines

Purpose

To assist in identifying medicines with the potential for increasing the risk of falls.

Description

Medicines can be associated with increased risk of falls, either due to their sedative effects, cognitive effects or hypotensive effects.⁸⁸⁻⁹⁰ Lists of medicines that have been shown to be associated with increased risk of falls have been created to assist assessment of the potential for risk from medicines, and in particular the risk due to concurrent use of medicines that each individually can contribute to risk of falls, as the effects can be cumulative.73 STOPPFall (Screening Tool of Older Persons Prescriptions in older adults with high fall risk) is one falls risk took that has been developed by the European Geriatric Medicine Society (EuGMS) Task and Finish Group on FRIDs (Falls risk increasing drugs).⁹¹ It contains 14 medicine classes: anticholinergics, diuretics, alpha-blockers used as antihypertensives, opioids, antidepressants, antipsychotics, antiepileptics, benzodiazepines and benzodiazepine-related medicines. STOPPFALL has associated deprescribing advice to support cessation of medicines where appropriate. The decision tool is available⁹² at: kik.amc.nl/falls/decision-tree/

The NSW Therapeutic Advisory Group have created a medication related fall risk assessment tool, which is designed for the hospital setting to be used within the polypharmacy quality use of medicines indicators.⁹³ The NSW Therapeutic Advisory Group tool includes a list of medicines with potential for increasing the risk of falls. The list is available online⁹⁴ at: www.nswtag. org.au/wp-content/uploads/2020/11/NSW-TAG-8.2_Med-related-Falls-Risk-Assessment-ToolMFRAT.pdf

Setting

Applicable across all health settings, although some lists have been developed for specific settings.

Audience

Health professionals.

Method of development

STOPPFall was developed using a three round Delphi process involving 24 experts. The initial list of medicines was based on evidence reviews of the association between medicines and falls.⁹¹

Advantages

The lists enable easy identification of medicines most likely to contribute to falls



and allows for consideration of the cumulative burden where multiple medicines that could contribute to falls risk are used. Research has shown that the effects of these medicines can be cumulative^{73, 95} that people taking these medicines can have changes in their gait,⁹⁶ are at increased risk of falls,^{97, 98} and have higher health care utilization.⁹⁸

Limitations

Tools developed internationally may include medicines, dosages or formulations not available in Australia. Medicines are not the only factor that contribute to falls risk and the medicines lists are sometimes incorporated into broader falls risk scores, such as psychological factors and cognitive status. See as an example the tool published by the Victorian Health Department.⁹⁹ at: <u>health.vic.gov.au/publications/falls-risk-</u> assessment-tool-frat

Data required

Medication chart for the medications. Patient interview for the full falls risk assessment scores.

Scottish Polypharmacy Guidance: Cumulative Toxicity tool and adverse drug reactions (ADR)

Purpose

To provide a visual aid for assessing the potential for more than one medicine to contribute to adverse medicine events.

Description

The Scottish Government Polypharmacy Model of Care Group 2018 have developed guidance to prevent inappropriate polypharmacy.¹⁰⁰ The guidance includes a visual tool to identify medicines that may contribute to the risk of the same adverse medicine event. The Scottish tool identifies 15 potential adverse events commonly associated with medicines and 32 medicine groups or classes that are frequently used. It is available online¹⁰¹ at: www.therapeutics. scot.nhs.uk/wp-content/uploads/2018/04/ Polypharmacy-Guidance-2018.pdf The tool has been adapted and developed as an interactive calculator as part of the Australian Veterans' Medicines Advice and Therapeutics Education Services Program.¹⁰² The interactive tool can demonstrate how potential risks change if medicines were to be prioritise for cessation. The interactive tool is available online.¹⁰³

Method of development

Medicines were classified as potentially contributing to the adverse event if the side effect was listed in the product information at a frequency of greater than 1 in 10,000 or based on the pharmacological profile of the medicine. The tool is limited to commonly used medicines and identifies medicines that have potential for each adverse event.

Setting

Applicable across all health settings.

Audience

Health professionals.

Advantages

The tool provides a visual cue for potential harms, including cumulative harms, from medicines.

Limitations

The tool does not estimate cumulative risk and does not account for dose or patient characteristics. The tool provides a visual cue only and is not exhaustive of all medicines or adverse events.

Data required

Medication chart.

Example

The example below is created from the web version of the tool and represents the adverse events that may be associated with medicine use for a person taking celecoxib, enalapril, temazepam, verapamil and citalopram.

🔥 Veterans' MATES	Australian Government Department of Veterans' Affairs	For Veterans and Carers For Health Professionals	=
Cumulative Risk (ielect medicines below to visua dverse drug reactions below an	Calculat lise their cumul re listed.	Or	
Q cita		Cumulative risks and types of adverse drug reactions	
		Medicine class risk count →	
Escitalopram		0 1 2 3 4 5 Falls and fracture - - - - - Renal injury - - - - -	
NSAID	^	Bleeding -	
Celecoxib	×	Heart failure	
ACE or ARB	^	CNS depression	
Enalapril Maleate	×	Constipation -	
Benzodiazepine	^	Urinary retention	
Temazepam	×	Serotonin syndrome	
CCB (non-dihydropyridine)	^	Bradycardia -	
Verapamil Hydrochloride	×	Hyperkalemia -	
	~	Hypokalemia -	
SSRI or SNRI			

Source

Example created from Cumulative Risk Calculator,¹⁰³ available at: <u>www.veteransmates.net.au/cumulative-risk-calculator/</u>

Medichec

Purpose

To provide a visual aid for identifying medicines with the potential for anticholinergic effects, QTc prolongation, hyponatremia, bleeding, dizziness, drowsiness, and constipation.

Description

Medichec is a free, web-based application to help healthcare professionals in identifying medicines that might have an effect on cognitive function in older adults as well as other adverse effects.¹⁰⁴ The tool features an Anticholinergic Effect on Cognition (AEC) scale¹⁰⁵ which aims to score medicines on their anticholinergic effect on cognition. The tool allows users to input a patient's medicines and receive an AEC score indicating the cumulative anticholinergic burden. A score of 3 or above suggests the need for a medicine review. Medichec also identifies other adverse effects, including QTc prolongation, hyponatremia, bleeding, dizziness, drowsiness, and constipation.

The tool categorises risk for individual medicines according to colour codes: red, amber, yellow, or blue. The colour ratings are based on the reported frequency of side effects, more so than the severity of the effects, with red indicating a higher frequency. Green indicates safe to use, and grey is used to indicate there is limited data. The tool is available online¹⁰⁶ at: www.medichec.com/

Method of development

The tool was developed by researchers at South London and Maudsley National Health Services (NHS) Foundation Trust and is based on medicines information from the British National Formulary (BNF).¹⁰⁴ The anticholinergic's effect is assessed using AEC score, which was developed based on in vitro anticholinergic potency as well as a medicine's capacity to cross the blood-brain barrier, information from medicine information texts.¹⁰⁵

Setting

Applicable across all health settings.

Audience

Health professionals.

Advantages

The tool provides a visual cue for the total score of anticholinergic effects. Additionally, Medichec features a color-coded system that categorises adverse effects, making it easier for clinicians to prioritise attention to higherrisk medicines and enhance patient safety.

Limitations

List of medicines are limited to those available in the United Kingdom.

Data required

Medication chart.

Example

The example below is created from the web version of the tool.



Source

Example created from Medichec Calculator,¹⁰⁶ available at: <u>www.medichec.com/w</u>

Tools supporting symptom assessment for adverse medicine event identification

The tools in the previous section identified possible side effects based on the known side effects of medicines prescribed. Patient self-report is another way to identify possible side effects from medicines. There are numerous patient questionnaires developed to assist side effect detection.¹⁰⁷ In this section, we describe two tools that ask patients to report symptoms that are possible related to medicines which have been developed to support detection of side effects of medicines during medicines review.

Patient Reported Outcome Measure Inquiry into Side-Effects (PROMISE)

Purpose

The patient reported outcome measure inquiry into side effects is designed to assist health professionals to identify side effects from medicines by inquiring about patient reported symptoms.¹⁰⁸

Description

The tool is a structured self-report questionnaire that contains a list of 22 common symptoms that could be due to the effects of medicines.¹⁰⁸ The tool is designed for self-administration by patients. The tool identifies symptoms and whether patients consider the symptoms may be related to their medicines. The tool includes questions on self-rated health, beliefs about medicines, and questions related to adherence. The full tool is available online¹⁰⁹ at: <u>pmc.</u> <u>ncbi.nlm.nih.gov/articles/instance/5840243/</u> <u>bin/11096_2017_575_MOESM1_ESM.pdf</u>

Method of development

The symptoms were selected based on the side effect profile of the most common medicines in use in the Netherlands. Side effects were grouped into symptom categories and limited to a set of the 22 symptoms likely to be most frequent. Expected frequency was based on side effect occurrence rate and number of medicines with that side effect. The final list was compared with published lists and reviewed by the research team.¹⁰⁸ Testing of the symptom list with patients prior to commencement of a medicine review found that patients were more likely to report a symptom if they were taking a medicine that had that symptom listed as very common in the product information.¹¹⁰

Setting

Designed to be used as part of a medicine review.

Audience

People taking medicines.

Advantages

Can be completed by patients and provides capacity for patients to identify whether they think the medicine is a contributing factor.

Limitations

Answers are limited to yes, no, unsure, thus severity of symptoms is not considered. Temporality of symptoms in relation to medicine use is also not assessed. The tool only supports detection of symptoms listed. The tool does include an open-ended question to allow respondents to identify other symptoms they consider may be medicine related.

Data required

Patient self-report.

Example

The symptom score component of the Patient Reported Outcome Measure Inquiry into Side-Effects is presented on the next page.¹¹⁰



Suffering from one of the following symptoms

To what extent did you suffer from one of the following symptoms in the last month? Can you indicate whether you think this may be a side effect of one of your medications.

	l suffered from the following symptom last month		This symptom w my medications	as possibly a sid	e effect of one of
Symptom	Yes	No	Yes	No	Do not know
Change of appetite	0	0	0	0	0
Dry mouth / thirst, mouth complaints	0	0	0	0	0
Nausea, vomiting	0	0	0	0	0
Stomach pain, dyspepsia	0	0	0	0	0
Abdominal pain	0	0	0	0	0
Diarrhoea	0	0	0	0	0
Constipation	0	0	0	0	0
Flatulence	0	0	0	0	0
Eye irritation, vision problems	0	0	0	0	0
Palpitations	0	0	0	0	0
Trembling, shivering	0	0	0	0	0
Muscle pain, joint pain	0	0	0	0	0
Muscular weakness	0	0	0	0	0
Headache	0	0	0	0	0
Dizziness, vertigo, fainting	0	0	0	0	0
Weakness, tiredness	0	0	0	0	0
Drowsiness	0	0	0	0	0
Change of mood	0	0	0	0	0
Sexual complaints	0	0	0	0	0
Bruises, bleeding	0	0	0	0	0
Skin complaints, itching	0	0	0	0	0
Sweating	0	0	0	0	0
Other:	0	0	0	0	0

Source

Patient-Reported Outcome Measure, Inquiry into Side Effects' (PROMISE) instrument. Creator Schoenmakers TW, Teichert M, Wensing M, de Smet PA.,¹¹⁰ Available under creative commons CC by 4.0³⁰ available online¹⁰⁹ at: <u>pmc.ncbi.nlm.nih.gov/articles/</u> instance/5840243/bin/11096_2017_575_MOESM1_ESM.pdf



PHASE 20 and Phase PROXY

Purpose

Self-report tools designed to detect symptoms related to medicines.

Description

Phase 20 was developed to detect symptoms related to medicines for aged care residents¹¹¹ and Phase Proxy was developed to detect symptoms related to medicines among persons with cognitive impairment.¹¹² Both tools are structured self-report questionnaire that contains a list of 19 common symptoms that could be due to the effects of medicines and one open ended question. The tools are intended for patient or carer self-completion with the aid of a health professional. PHASE 20 includes a four-point response to indicate symptom severity, from no problem, minor, moderate, or severe problem. Phase Proxy has four response options: no, mild/occasionally, severe/often, do not know. Copies of the tools are available online¹¹³ at: regionuppsala. se/samverkanswebben/for-vardgivare/ kunskapsstod/lakemedel/tillgangliga-resurservid-lakemedelsbehandling/apotekare-ivarden/phase-20/phase-20-english/

The tools require permission from the author to be used outside Sweden.

Method of development

Phase 20¹¹¹ was developed based on a literature search for common symptoms related to medicine use in older people and geriatricians and clinical pharmacist expert input. An initial list of symptoms was trialled and compared with a pharmacist's assessment of the likelihood the symptom was medicine related, and subsequently reviewed by a geriatrician and clinical pharmacist. Correlations between symptoms were also explored, with correlated symptoms merged into one symptom group.

In developing Phase Proxy, three expert groups involving dementia experts and health officials involved in dementia, registered nurses with expertise in dementia, and geriatricians and clinical pharmacists, reviewed Phase 20 with the aim of removing subjective terms and replacing them with objective alternatives, as well as identifying any symptoms relevant to dementia medicines that may have been missing. The response scale was limited to three items, was then tested for inter-rater reliability, internal consistency, and content validity.¹¹²

Setting

The tool was designed to be used as part of a medicine review.

Audience

People taking medicines or their carers.

Advantages

This tool is routinely used in Sweden and is available in English versions.

Limitations

Use outside of Sweden requires permission.

Data required

Patient or carer interview.



The tools in the previous section identify particular types of medicine related problems. Some tools have also been developed to identify people at risk of medicine related problems in general.¹¹⁴⁻¹¹⁷ People may be at risk of medicine related problems due to medicine related factors, but factors related to the person taking the medicines as well as systems factors can also put people at risk of medicine related problems. Knowing who is at risk of medicine-related problems can be helpful for triaging persons for a medicines review. On some occasions, such as where there are resource constraints, there is also a need to prioritise medicine review services to the persons most at risk of medicine related harms.

In this section of the handbook we highlight tools to identify people at risk of medicine related problems, and a risk calculator, developed in Australia, to predict which patients may benefit most from a medication review.

Self-Medication Risk Assessment Instrument

Purpose

A screening tool to identify people at risk of medicine-related problems.

Description

The tool contains¹¹⁸ seven items relating to the number of medicines taken, the person's mental state, hearing, vision, social circumstances, physical condition, and attitude and knowledge about medications. The tool was developed as a 4 point scale ranging from 1 =no risk to 4 = high risk, judged against explicit criteria for each risk level. Scores for each item are summed for a total score.

The tool is published in the appendix of the paper¹¹⁸ available at: <u>www.sciencedirect.com/</u> <u>science/article/pii/S136190040500004X#app1</u>

Method of development

Key factors affecting older people's ability to manage their medicines were identified through literature review and interviews with consumers, carers, and health professionals. The tool was tested on 45 people. Each person was assessed by 2 assessors (nurses, pharmacists or social care workers) to determine inter-rater reliability and one assessor revisited the person a week later to determine intra-rate reliability. The tool was found to have high inter-rater reliability and criterion validity.¹¹⁸

Audience

Health care professionals.

Setting

Primary care.

Advantages

Simple to administer and score and brief to administer. The tool is in use in the UK as a 6 item scale (hearing has been omitted) with modified scoring for each item. In this modified tool, a score of 13 or less is considered lowrisk, 14 to 16 medium risk, 17 to 22 high risk and 23 or above very high risk.¹¹⁹ Guidance for health care professionals for suggested actions for each risk level is provided in the with accompanying material.¹¹⁹ It is available online¹¹⁹ at: <u>bradford.connecttosupport.org/</u> <u>media/q5xpozqd/appendix-a-fuller-s-self-</u> <u>medication-risk-assessment-screening-tool.pdf</u>

Limitations

The score does not account for the type of medicine, dose prescribed or frequency of dosing. The tool relies on assessment by the health care professional or reliable consumer self-report.

Data required

Patient interview.

Example

The following provides an example of Self Medication Risk Assessment tool.



Paula is an 81-year old female living alone in the community with no support. She takes multiple medicines, is oriented but sometimes forgetful, hears well, needs glasses to read, and can manage to open bottles and packets independently. She is fairly interested in her medicines and knows enough about them to administer them safely, and believes they are important.

Her medications include

- Pantoprazole 40mg daily
- Apixaban 5mg twice a day
- Irbesartan 150mg with hydrochlorothiazide

Score	1	2	3	4	Enter Score Below
Number of prescribed medications	1 medicine	2 medicines	3 medicines	4 or more medicines	3
Mental State	Alert and orientated	Orientated but sometimes forgetful	Confused, muddled/ disorientated/ very forgetful	Very confused	2
Hearing	Can hear without a hearing aid	Needs hearing aids to hear properly	Difficulty hearing even with hearing aids	Unable to hear	1
Vision	Can see to read with no aids	Needs glasses/aids to read and print	Difficult to read print with glasses/ aids	Unable to see	2
Social Circumstances	Living with others who can fully support medication needs	Living with others who usually/ sometimes support medication administration	Living with others with some support from paid carers or family/friend	Living alone with no support	4
Physical Condition	Can mange to open bottles/packet independently	Weakness of hand/ poor coordination but can manage to open bottles/packet with difficulty	Disabled. Requires some help to open packages	Severely disabled unable to manage	1
Attitude and knowledge about medications	Interested about prescribed medications and knows all about them, believes they are important	Fairly interested about prescribed medications and knows enough about them to administer them safely/believes they are important	Not very interested about prescribed medications. Does not believe they are important/unable to recall medication regime	Disinterested and or unwilling to take prescribed medication	2
Total score					15

Source

Fuller et al. Clinical Effectiveness in Nursing, 2005; 9: 78-83¹¹⁸



Medication risk checklist for older adults (LOTTA)

Purpose

A self-assessment tool for older adults living independently to identify persons at risk of medicine related problems.

Description

The tool¹²⁰ contains eight items, three of which relate to systems issues including whether there is an up-to-date medicines list, multiple doctors involved in their care, and whether there is follow-up care planned. One of the items relates to possible medicine related symptoms, one relates to adherence and the remaining relate to self-management assessment. The tool is published as open access and available online¹²⁰ at: www.tandfonline.com/doi/full/10.1080/078538

90.2023.2287707#d1e405

Method of development

The tool was developed based on an existing nurse administered medicine related problem tool and published literature. A three round Delphi method was undertaken with 19 experts in geriatrics and therapeutics to determine content validity, with the feasibility tested among 87 older adults.¹²⁰

Audience

Older people living in the community.

Setting

Primary care.

Advantages

This tool can be self-administered and covers the range of medicine-related problems from systems issues, patient factors, and medication issues. The feasibility study suggests it takes six minutes to complete.¹²⁰

Limitations

The tool is self-administered, with active follow-up required to ensure health professionals are aware of the results. The tool was developed in Finland and some of the language may not be applicable to the Australian health system.

Data required

Consumer self-report.

PHarmacie-R

Purpose

To identify patients in the hospital setting who should be prioritised for early medicine review post-discharge because they are at high risk of readmission.

Description

PHarmacie-R is a smart phone based predictive tool developed to identify patients in the hospital setting who should be prioritised for medicine review.¹²¹ The model was based on its ability to predict patients at risk of hospital readmission within 90 days. Variables included in the model were patient factors including: age, sex, Aboriginality, domiciliary status (living alone), geographic isolation (rural or remote), need for an interpreter; morbidities (mental illness or cognitive impairment), multimorbidity (three or more comorbidities); health service use (unplanned emergency department attendance or hospital admission in the last 6 months); and medicine use (polypharmacy defined as five or more medicines), and use of high risk medications.¹²¹ The final model was found to have a positive predictive value of 59% and a negative predictive value of 72%. A model score of 0.46 was considered to give the best separation between low and high risk. A cut off of 0.4 was found to identify patients with moderate risk.¹²¹

PHarmacie-R Risk Score = e^a/(1+e^a)

Where a = -7.065131

- + 0.6787006*gender (Male=1, Female =0)
- + 0.2680293*age-0.004810423*age²+ 0.00002604254*age³ (age in years)
- + 0.03076355*polypharmacy (5 or more medicines =1, less than five =0)
- + 0.44733076*high risk medicines (One or more = 1, none =0)
- + 0.5300211*lives alone (Yes = 1, No-=0)
- + 0.2275686*lives rural or remote location (Yes=1, No=0)
- + 0.3811697*history of mental Illness or cognitive impairment (Yes = 1, No=0)
- + 1.030316*comorbidities (3 or more = 1, 2 or less =0)
- 0.2385641* Indigenous or interpreter (Yes=1, No=0)
- + 0.1958415*length of stay in hospital (5 or more days =1, 4 or less days =0)
- + 0.8111112*readmission or emergency department attendance within 6 months (Yes = 1, No = 0)

Method of development

The model was developed using logistic regression and built on an earlier version, PHarmacie-4, that was a simple to use tool that summed ten predictor variables, with a score of four or more, considered high risk.¹²² While simple to use, PHarmacie 4 over-estimated risk, thus, is not suitable for use in practice. PHarmacie-R included the risk factors used in PHarmacie 4 and logistic regression models were run to determine the risk prediction based on the inclusion of subsets or the complete set of risk factors. The models were developed on a sample of 1201 patients, and then tested for applicability in a sample of 200 patients where the positive predictive value for the applicability sample was found to be 54.2% and the negative predictive value 70.6%.¹²¹

Audience

Health professionals.

Setting

Developed for the hospital setting.

Advantages

This is an Australian based risk calculator for use in the hospital.

Limitations

Its generalisability outside the setting in which it was developed is not known. Manual calculation is time consuming.

Data required

Risk factors can be collected by patient interview, and review of the medication chart and clinical record.



Example

The following provides an example of the PHarmacie-R-Risk Score.

Person

Ron is a 78-year-old male with multiple comorbidities who has been in hospital for the last five days. He lives alone in country Victoria. He doesn't need an interpreter and does not identify as Indigenous. He has no cognitive impairment. He has not been in hospital or the emergency department in the last six months.

His comorbidities include:

- Ischaemic Heart Disease
- Hypertension last office BP was 118/75
- Atrial fibrillation (AF)
- Gastroesophageal reflux disease (GORD)
- Chronic low back and neck pain
- Overweight

His medications include:

- Diclofenac 50 mg twice a day as needed
- Apixaban 5 mg twice a day
- Aspirin 100 mg daily
- Rosuvastatin 10 mg daily
- Pantoprazole 40 mg daily
- Citalopram 20 mg daily
- Oxazepam 15 mg before bed as needed
- Atenolol 25 mg twice a day
- Amlodipine 5 mg daily
- Irbesartan 150 mg with hydrochlorothiazide 12.5 mg daily
- Glyceryl trinitrate (GTN) spray as needed for chest pain

PHarmacie-R Risk Score = e^a/(1+e^a)

Where a = -7.065131

- + 0.6787006*1 (gender)
- + 0.2680293*78 0.004810423*782+ 0.00002604254*783 (age)
- + 0.03076355*1 (polypharmacy)
- + 0.44733076*0 (high risk medicines)
- + 0.5300211*1 (lives alone)
- + 0.2275686*1 (lives rurally)
- + 0.3811697*1 (Mental illness)
- + 1.030316*1 (comorbidities)
- 0.2385641* 0 (Indigenous or interpreter)
- + 0.1958415*1 (length of stay)
- + 0.8111112*0 (readmissions)

Final score = 0.57

This score is above the cut-off of 0.46 (or 0.40), thus Ron would be identified as a candidate for early mediation review post discharge using this tool.

Tools to support identification of patients suitable for deprescribing

In previous sections, we highlighted tools that assist with identifying medicines that are potentially inappropriate or lead to harms. Having identified medicines that potentially could or are causing harms, the next step is to switch to a more appropriate alternative or to cease the medicine, often referred to as deprescribing.123 While some medicines can be stopped immediately, many others need to be tapered to prevent rebound or withdrawal symptoms. Some of the tools already considered, including MedStopper and STOPPFall (see tools to assist identification of cumulative toxicity) include recommendations for cessation of medicines. Person-centred care is also considered key to support deprescribing, with patient and carer engagement and agreement necessary when considering changes to the medicine regimen. In this section of the handbook, we highlight a tool developed in Australia to identify patient attitudes towards deprescribing, the knowledge from which could be used to support successful deprescribing of medicines.

Patient attitudes towards deprescribing questionnaire

Purpose

To elicit consumer attitudes towards their medicines.

Description

The Patient Attitudes Towards Deprescribing questionnaire aims to identify patient attitudes towards deprescribing and support patient centred care. Originally developed in 2012^{124,} ¹²⁵ the questionnaire was revised in 2016 with versions produced for older adults as well as carers of older people.¹²⁶ The revised questionnaires include 22 questions in the version for older adults and 19 questions in the version for carers. The questionnaires address four themes: i) belief in appropriateness of withdrawal; ii) perceived burden of their medications; iii) concerns about stopping; and iv) level of involvement in medication management".¹²⁶ A version for people living with cognitive impairment has also been developed.^{127, 128}

The questionnaires can be used freely for non-commercial research with permission. And can be used by healthcare professionals (for non-commercial purposes) available at: www.australiandeprescribingnetwork.com. au/925-2/

An electronic version of the questionnaire is available for use by Australian registered healthcare practitioners after registering for an account⁷⁷ at: <u>gmedss.com/about</u>

Setting

Suitable for use in all health settings.

Audience

Suitable for use by any health practitioner; the questionnaires can be self-administered by consumers.

Method of development

The questionnaire was originally developed based on expert opinion and evidence from the literature on patients views about medicines, revised after pilot testing with patients and expert review, and then tested for face, content and criterion validity, sensitivity and test–retest reliability.¹²⁵ The revised questionnaire retained items from the original questionnaire with additional questions generated from the literature, expert opinion and focus groups. The revised questionnaires were subsequently tested for face, content, construct, internal consistency, and criterion validity as well as test-retest reliability with patients and carers.¹²⁶

Advantages

The tool has been validated and is widely used in research studies and provides a method for identifying patients most likely to be active partners in deprescribing. A longitudinal Swiss study found that a reluctance to cease medicine, as measured by the tool, was associated with increased use of medicines at 12 months follow-up,¹²⁹ however; this study



did not use the respondent's answers to the questionnaire to target the intervention. A study in Ireland found that willingness to deprescribe was associated with a higher rate of deprescribing.¹³⁰ However, other studies have not found this association¹³¹ and so further research is required.

Limitations

The best approach to use the tool in practice is still under investigation.

Data required

Patient or carer interview.

Tools to support medication switching and tapering

When medicines need to be switched, dose equivalence is an important consideration. Some medicines require tapering for effective switching to ensure symptom control and minimise side effects. Tapering is also a consideration when medicines need to be ceased, particularly for medicines that have withdrawal, rebound or addictive effects. In this section of the report, we highlight examples of available switching and tapering calculators. Consideration should be given to the method of development of any switching or tapering tool prior to use, as there are a number of web-based tools directed to consumers to create tapering plans for psychotropic medicines, not all of which indicate the source of information on which the tool is based or the developer.

Medicine switching calculators

Purpose

Designed to assist in selecting equivalent medicine dosages to support switching.

Description

There are a number of tools available to support clinicians to switch medicines at equivalent dosages, including where tapering of doses is required to successfully effect the switch. The majority of tools relate to analgesic and psychotropic medicines.

Method of development

The majority of tools have been developed by health professional organisations or medicines information specialists.

Setting

Suitable for use in all health settings.

Audience

Suitable for use by any health practitioner, however, some medicines may be specialist managed.

Advantages

Simple to use with some producing a visual switching plan.

Limitations

Products available in Australia may not be available in strengths that match the calculated doses. Consideration will need to be given to which strength best matches the calculated dose. The tools generally do not consider patient related factors, other conditions and medicines which may need to be taken into account.

Data required

Medication regimen



Examples

Opioid switching calculator

The Faculty of Pain Medicine, Australia and New Zealand College of Anaesthetists has developed an opioid calculator to support switching of opioids based on morphine equivalent doses either to an equivalent doses or at reduced doses, with the ability to create different dose recommendations based on the percentage dose reduction required.¹³² The tool is available as a smart phone app and online¹³³ at: www.opioidcalculator.com.au/

The example below is sourced from the calculator and shows an equianalgesic dose calculation from morphine to oxycodone, and at percentage dose reductions.

Equianalgesic Dose

- 30mg/day Morphine
- Doses for oxycodone oral
 - 20mg/day
 - 15mg/day (at 25% reduction)
 - 14mg/day (at 30% reduction)
 - 12mg/day (at 40% reduction)
 - 10mg/day (at 50% reduction)

Source¹³³

Created using www.opioidcalculator.com.au/

SwitchRx

SwitchRx is an online medication switching resource designed for Canadian healthcare professionals managing psychotropic treatments. The tool is structured to allow users to select specific classes of psychotropic medications, such as antipsychotics, antidepressants, or hypnotics. The tool provides evidence-based, up-todate guidance on transitioning between these medications. It includes detailed protocols, practical tips, and considerations for tapering, cross-titration, and substitution strategies. SwitchRx is available after account registration¹³⁶ from: www.switchrx.com/

Antipsychotic switching calculator

Australian Prescriber publish a calculator to support switching of antipsychotics at equivalent dosing, currently in its fifth version.134, 135 It includes switching between oral products or depot to depot, with the output indicating the switching regimen by indication. The tool is available online¹³⁵ at: <u>australianprescriber.tg.org.au/articles/</u> <u>antipsychotic-switching-tool.html</u>

The example below of a switch is created from the web version of the tool.¹³⁵

Direct switch and cross titration

If risperidone was prescribed in doses above 3 mg daily, the dose should be reduced to 50% on day 1 and then stopped at day 5.

For bipolar depression, immediate- or modified-release quetiapine should be administered once daily at bedtime and titrated from a low dose.

A suggested regimen is:

- 50 mg on day 1
- 100 mg on day 2
- 200 mg on day 3
- 300 mg on day 4.

The dose may be adjusted up to 600 mg/day in increments of 100 mg/day depending on clinical response and tolerability

Source¹³⁵

Created using <u>australianprescriber.tg.org.au/articles/</u> antipsychotic-switching-tool.html



Purpose

Designed to assist in selecting dosages and time intervals to support successful cessation of medicines.

Description

There are a number of tools available to support clinicians to taper medicines. The majority of tools relate to analgesic and psychotropic medicines.

Method of development

The majority of tools have been developed by health professional organisations or medicines information specialists.

Setting

Suitable for use in all health settings.

Audience

Suitable for use by any health practitioner; however, some medicines may be specialist managed.

Advantages

Simple to use with some producing a visual switching plan.

Limitations

For internationally based calculators, products available in Australia may not be available in strengths that match the calculated doses. Consideration will need to be given to which strength best matches the calculated dose. The tools generally do not consider patient related factors, other conditions and medicines which may need to be taken into account.

Data required

Medication regimen.





Examples

An Australian opioid tapering calculator has been developed by the Victorian Department of Health and NPS Medicines Wise.¹³⁷ This calculator requires the initial medicine, the daily dose, the target change (to another medication or to cease) and the tapering rate. It provides a visual display of the tapering regimen and allows variable tapering rates to be calculated. It is available for download¹³⁷ at: <u>www.health.vic.gov.au/publications/opioidtapering-calculator</u> The example below shows the dosage suggestions for tapering oxycodone from a starting dose of 30mg per day by 20% each week.



Source¹³⁶

Created using www.health.vic.gov.au/publications/opioid-tapering-calculator



The West of Scotland Chronic Pain Education Group also have an opioid switching and tapering calculator.¹³⁸ This calculator requires the initial medicine, the daily dose, the target change (to another medication or to cease) and the tapering rate. This is a UK tool and product strengths and formulations may vary to the Australian market. The opioid tapering calculator¹³⁹ and the opioid switching calculator¹⁴⁰ is available at: paindata.org/taper.php

The tapering example below for oxycodone 70mg as a starting dose with a 15% reduction rate is created from the web version of the tool.

Before using, please read the disclaimer

Select an initial medication. 2) Select a starting 24h dose. 3) Select a target medication.
 Select a rate of taper (higher rates result in a shorter taper period).



Source¹³⁹ Created using <u>paindata.org/taper.php</u>

- Nguyen H, Manolova G, Daskalopoulou C, Vitoratou S, Prince M, Prina AM. Prevalence of multimorbidity in community settings: A systematic review and meta-analysis of observational studies. J Comorb. 2019;9:2235042X19870934.
- Arnone D, Omar O, Arora T, Ostlundh L, Ramaraj R, Javaid S, et al. Effectiveness of pharmacogenomic tests including CYP2D6 and CYP2C19 genomic variants for guiding the treatment of depressive disorders: Systematic review and meta-analysis of randomised controlled trials. Neurosci Biobehav Rev. 2023;144:104965.
- Sutherland JJ, Daly TM, Liu X, Goldstein K, Johnston JA, Ryan TP. Co-prescription trends in a large cohort of subjects predict substantial drugdrug interactions. PLoS One. 2015;10(3):e0118991.
- Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. BMC Geriatr. 2017;17(1):230.
- Prasad N, Lau ECY, Wojt I, Penm J, Dai Z, Tan ECK. Prevalence of and Risk Factors for Drug-Related Readmissions in Older Adults: A Systematic Review and Meta-Analysis. Drugs Aging. 2024;41(1):1-11.
- Yadesa TM, Kitutu FE, Deyno S, Ogwang PE, Tamukong R, Alele PE. Prevalence, characteristics and predicting risk factors of adverse drug reactions among hospitalized older adults: A systematic review and meta-analysis. SAGE Open Med. 2021;9:20503121211039099.
- Davies LE, Spiers G, Kingston A, Todd A, Adamson J, Hanratty B. Adverse Outcomes of Polypharmacy in Older People: Systematic Review of Reviews. J Am Med Dir Assoc. 2020;21(2):181-7.
- Morath B, Mayer T, Send AFJ, Hoppe-Tichy T, Haefeli WE, Seidling HM. Risk factors of adverse health outcomes after hospital discharge modifiable by clinical pharmacist interventions: a review with a systematic approach. Br J Clin Pharmacol. 2017;83(10):2163-78.
- Oscanoa TJ, Lizaraso F, Carvajal A. Hospital admissions due to adverse drug reactions in the elderly. A meta-analysis. Eur J Clin Pharmacol. 2017;73(6):759-70.
- Lim R, Ellett LMK, Semple S, Roughead EE. The Extent of Medication-Related Hospital Admissions in Australia: A Review from 1988 to 2021. Drug Saf. 2022;45(3):249-57.
- Wimmer BC, Cross AJ, Jokanovic N, Wiese MD, George J, Johnell K, et al. Clinical Outcomes Associated with Medication Regimen Complexity in Older People: A Systematic Review. J Am Geriatr Soc. 2017;65(4):747-53.

- Elliott RA. Reducing medication regimen complexity for older patients prior to discharge from hospital: feasibility and barriers. J Clin Pharm Ther. 2012;37(6):637-42.
- Richter A, Anton SF, Koch P, Dennett SL. The impact of reducing dose frequency on health outcomes. Clin Ther. 2003;25(8):2307-35; discussion 6.
- 14. Sluggett JK, Stasinopoulos J, Sylvester C, Wong WJ, Hillen J, Hughes GA, et al. Simplifying medication regimens for residents of aged care facilities: Pharmacist and physician use of a structured five-step medication simplification tool. Res Social Adm Pharm. 2024;20(8):733-9.
- George J, Phun YT, Bailey MJ, Kong DC, Stewart K. Development and validation of the medication regimen complexity index. Ann Pharmacother. 2004;38(9):1369-76.
- McDonald MV, Peng TR, Sridharan S, Foust JB, Kogan P, Pezzin LE, et al. Automating the medication regimen complexity index. J Am Med Inform Assoc. 2013;20(3):499-505.
- Libby AM, Hirsch JD. Electronic Data Capture and Coding Tool for Medication Regimen Complexity University of Colorado,: The Regents of the University of Colorado,; 2024 [Available from: pharmacy.cuanschutz.edu/research/MRCTool.
- Libby AM, Fish DN, Hosokawa PW, Linnebur SA, Metz KR, Nair KV, et al. Patient-level medication regimen complexity across populations with chronic disease. Clin Ther. 2013;35(4):385-98 e1.
- Ferreira JM, Galato D, Melo AC. Medication regimen complexity in adults and the elderly in a primary healthcare setting: determination of high and low complexities. Pharm Pract (Granada). 2015;13(4):659.
- Morillo-Verdugo R, Robustillo-Cortes MA, Abdel-Kader Martin L, Alvarez de Sotomayor Paz M, Lozano de Leon Naranjo F, Almeida Gonzalez CV. Determination of a cutoff value for medication regimen complexity index to predict polypharmacy in HIV+ older patient. Rev Esp Quimioter. 2019;32(5):458-64.
- Alves-Conceicao V, Rocha KSS, Silva FVN, Silva ROS, Silva DTD, Lyra-Jr DP. Medication Regimen Complexity Measured by MRCI: A Systematic Review to Identify Health Outcomes. Ann Pharmacother. 2018;52(11):1117-34.
- Lee S, Jang J, Yang S, Hahn J, Min KL, Jung EH, et al. Development and validation of the Korean version of the medication regimen complexity index. PLoS One. 2019;14(5):e0216805.



- Okuyan B, Babi B, Sancar M, Ay P, Yucel E, Yucel A, et al. Validation of the Turkish version of medication regimen complexity index among elderly patients. J Eval Clin Pract. 2016;22(5):732-6.
- 24. Saez de la Fuente J, Such Diaz A, Canamares-Orbis I, Ramila E, Izquierdo-Garcia E, Esteban C, et al. Cross-cultural Adaptation and Validation of the Medication Regimen Complexity Index Adapted to Spanish. Ann Pharmacother. 2016;50(11):918-25.
- Melchiors AC, Correr CJ, Fernandez-Llimos F. Translation and validation into Portuguese language of the medication regimen complexity index. Arq Bras Cardiol. 2007;89(4):210-8.
- Chen EY, Sluggett JK, Ilomaki J, Hilmer SN, Corlis M, Picton LJ, et al. Development and validation of the Medication Regimen Simplification Guide for Residential Aged CarE (MRS GRACE). Clin Interv Aging. 2018;13:975-86.
- Dugre N, Bell JS, Hopkins RE, Ilomaki J, Chen EYH, Corlis M, et al. Impact of Medication Regimen Simplification on Medication Incidents in Residential Aged Care: SIMPLER Randomized Controlled Trial. J Clin Med. 2021;10(5).
- Sluggett JK, Hopkins RE, Chen EY, Ilomaki J, Corlis M, Van Emden J, et al. Impact of Medication Regimen Simplification on Medication Administration Times and Health Outcomes in Residential Aged Care: 12 Month Follow Up of the SIMPLER Randomized Controlled Trial. J Clin Med. 2020;9(4).
- 29. Sluggett JK, Page AT, Chen EYH, Ilomaki J, Corlis M, Van Emden J, et al. Protocol for a nonrandomised pilot and feasibility study evaluating a multicomponent intervention to simplify medication regimens for people receiving community-based home care services. BMJ Open. 2019;9(7):e025345.
- Creative Commons. Attribution 4.0 International: Creative Commons; 2024 [Available from: www.creativecommons.org/licenses/by/4.0/.
- Konstantinou P, Kasinopoulos O, Karashiali C, Georgiou G, Panayides A, Papageorgiou A, et al. A Scoping Review of Methods Used to Assess Medication Adherence in Patients with Chronic Conditions. Ann Behav Med. 2022;56(12):1201-17.
- Fahrni ML, Saman KM, Alkhoshaiban AS, Naimat F, Ramzan F, Isa KAM. Patient-reported outcome measures to detect intentional, mixed, or unintentional non-adherence to medication: a systematic review. BMJ Open. 2022;12(9):e057868.
- Lam WY, Fresco P. Medication Adherence Measures: An Overview. Biomed Res Int. 2015;2015:217047.
- Svarstad BL, Chewning BA, Sleath BL, Claesson C. The Brief Medication Questionnaire: a tool for screening patient adherence and barriers to adherence. Patient Educ Couns. 1999;37(2):113-24.

- Svarstad BL. Brief Medication Questionnaire (BMQ-H9) 2006 [Available from: <u>www.pharmacy.</u> <u>wisc.edu/wp-content/uploads/2016/05/BMQ-H-9</u> <u>website2022.pdf</u>.
- Bailey SC, Annis IE, Reuland DS, Locklear AD, Sleath BL, Wolf MS. Development and evaluation of the Measure of Drug Self-Management. Patient Prefer Adherence. 2015;9:1101-8.
- Creative Commons. Attribution-NonCommercial 3.0 Unported [Available from: <u>creativecommons.org/</u> <u>licenses/by-nc/3.0/</u>.
- Morisky DE. Morisky Scales MMAS-4 & MMAS-8: Morisky Medication Adherence Research; 2024 [Available from: <u>www.moriskyscale.com/about-the-morisky-scale---mmas-4--mmas-8-the-morisky-scales.html</u>.
- Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24(1):67-74.
- Retraction Statement: Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens (Greenwich). 2023;25(9):889.
- Morisky DE, Ang A, Krousel-Wood M, Ward HJ. Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens (Greenwich). 2008;10(5):348-54.
- Moon SJ, Lee WY, Hwang JS, Hong YP, Morisky DE. Accuracy of a screening tool for medication adherence: A systematic review and meta-analysis of the Morisky Medication Adherence Scale-8. PLoS One. 2017;12(11):e0187139.
- 43. Moon SJ, Lee WY, Hwang JS, Hong YP, Morisky DE. Correction: Accuracy of a screening tool for medication adherence: A systematic review and meta-analysis of the Morisky Medication Adherence Scale-8. PLoS One. 2018;13(4):e0196138.
- Hanlon JT, Schmader KE, Samsa GP, Weinberger M, Uttech KM, Lewis IK, et al. A method for assessing drug therapy appropriateness. J Clin Epidemiol. 1992;45(10):1045-51.
- 45. Samsa GP, Hanlon JT, Schmader KE, Weinberger M, Clipp EC, Uttech KM, et al. A summated score for the medication appropriateness index: development and assessment of clinimetric properties including content validity. J Clin Epidemiol. 1994;47(8):891-6.
- Hanlon JT, Schmader KE. The Medication Appropriateness Index: A Clinimetric Measure. Psychother Psychosom. 2022;91(2):78-83.
- Hanlon JT, Schmader KE. The medication appropriateness index at 20: where it started, where it has been, and where it may be going. Drugs Aging. 2013;30(11):893-900.

- Lee G, Lim JF, Page AT, Etherton-Beer C, Clifford R, Wang K. Applicability of explicit potentially inappropriate medication lists to the Australian context: A systematic review. Australas J Ageing. 2022;41(2):200-21.
- Motter FR, Fritzen JS, Hilmer SN, Paniz EV, Paniz VMV. Potentially inappropriate medication in the elderly: a systematic review of validated explicit criteria. Eur J Clin Pharmacol. 2018;74(6):679-700.
- Inglis JM, Caughey G, Thynne T, Brotherton K, Liew D, Mangoni AA, et al. Inappropriate prescribing and association with readmission or mortality in hospitalised older adults with frailty: a systematic review and meta-analysis. BMC Geriatr. 2024;24(1):718.
- Corvaisier M, Brangier A, Annweiler C, Spiesser-Robelet L. Preventable or potentially inappropriate psychotropics and adverse health outcomes in older adults: systematic review and meta-analysis. J Nutr Health Aging. 2024;28(4):100187.
- Mekonnen AB, Redley B, de Courten B, Manias E. Potentially inappropriate prescribing and its associations with health-related and systemrelated outcomes in hospitalised older adults: A systematic review and meta-analysis. Br J Clin Pharmacol. 2021;87(11):4150-72.
- Schiavo G, Forgerini M, Lucchetta RC, Silva GO, Mastroianni PDC. Cost of adverse drug events related to potentially inappropriate medication use: A systematic review. J Am Pharm Assoc (2003). 2022;62(5):1463-76 e14.
- 54. Rodrigues RC, Gomes GKA, Sodre BMC, Lima RF, Barros DSL, Figueiredo A, et al. Lists of potentially inappropriate medications for older people in primary care: a systematic review of health outcomes. Cad Saude Publica. 2024;40(5):e00016423.
- 55. Hill-Taylor B, Walsh KA, Stewart S, Hayden J, Byrne S, Sketris IS. Effectiveness of the STOPP/ START (Screening Tool of Older Persons' potentially inappropriate Prescriptions/Screening Tool to Alert doctors to the Right Treatment) criteria: systematic review and meta-analysis of randomized controlled studies. J Clin Pharm Ther. 2016;41(2):158-69.
- Wang KN, Etherton-Beer CD, Sanfilippo F, Page AT. Development of a list of Australian potentially inappropriate medicines using the Delphi technique. Intern Med J. 2024;54(6):980-1002.
- 57. American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria(R) for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2023;71(7):2052-81.
- Sawan MJ, Clough A, Hillen J, Soulsby N, Gnjidic D. Comparison of polypharmacy and potentially inappropriate medication use in older adults with and without dementia receiving residential

medication management reviews. Australas J Ageing. 2024;43(3):628-35.

- Holdaway M, Hyde Z, Hughson JA, Malay R, Stafford A, Fulford K, et al. Medications and cognitive risk in Aboriginal primary care: a crosssectional study. Intern Med J. 2024;54(6):897-908.
- 60. O'Mahony D, Cherubini A, Guiteras AR, Denkinger M, Beuscart JB, Onder G, et al. Correction: STOPP/ START criteria for potentially inappropriate prescribing in older people: version 3. Eur Geriatr Med. 2023;14(4):633.
- O'Mahony D, Cherubini A, Guiteras AR, Denkinger M, Beuscart JB, Onder G, et al. STOPP/START criteria for potentially inappropriate prescribing in older people: version 3. Eur Geriatr Med. 2023;14(4):625-32.
- 62. Lavan AH, Gallagher P, Parsons C, O'Mahony D. STOPPFrail (Screening Tool of Older Persons Prescriptions in Frail adults with limited life expectancy): consensus validation. Age Ageing. 2017;46(4):600-7.
- Curtin D, Gallagher P, O'Mahony D. Deprescribing in older people approaching end-of-life: development and validation of STOPPFrail version 2. Age Ageing. 2021;50(2):465-71.
- 64. Frankenthal D, Israeli A, Caraco Y, Lerman Y, Kalendaryev E, Zandman-Goddard G, et al. Long-Term Outcomes of Medication Intervention Using the Screening Tool of Older Persons Potentially Inappropriate Prescriptions Screening Tool to Alert Doctors to Right Treatment Criteria. J Am Geriatr Soc. 2017;65(2):e33-e8.
- 65. Curtin D, Jennings E, Daunt R, Curtin S, Randles M, Gallagher P, et al. Deprescribing in Older People Approaching End of Life: A Randomized Controlled Trial Using STOPPFrail Criteria. J Am Geriatr Soc. 2020;68(4):762-9.
- 66. Pazan F, Weiss C, Wehling M, Forta. The FORTA (Fit fOR The Aged) List 2021: Fourth Version of a Validated Clinical Aid for Improved Pharmacotherapy in Older Adults. Drugs Aging. 2022;39(3):245-7.
- Pazan F, Weiss C, Wehling M, Members FEP. The EURO-FORTA (Fit fOR The Aged) List Version 2: Consensus Validation of a Clinical Tool for Improved Pharmacotherapy in Older Adults. Drugs Aging. 2023;40(5):417-26.
- Pazan F, Gercke Y, Weiss C, Wehling M, Raters F. The U.S.-FORTA (Fit fOR The Aged) List: Consensus Validation of a Clinical Tool to Improve Drug Therapy in Older Adults. J Am Med Dir Assoc. 2020;21(3):439 e9- e13.
- Pazan F, Weiss C, Wehling M, Forta. The EURO-FORTA (Fit fOR The Aged) List: International Consensus Validation of a Clinical Tool for Improved Drug Treatment in Older People. Drugs Aging. 2018;35(1):61-71.

Handbook of tools to support medicine management in multimorbidity and polypharmacy | University of South Australia, 2025

- Pazan F, Weiss C, Wehling M, Forta. Correction to: The EURO-FORTA (Fit fOR The Aged) List: International Consensus Validation of a Clinical Tool for Improved Drug Treatment in Older People. Drugs Aging. 2018;35(7):677.
- Wehling M, Burkhardt H, Kuhn-Thiel A, Pazan F, Throm C, Weiss C, et al. VALFORTA: a randomised trial to validate the FORTA (Fit fOR The Aged) classification. Age Ageing. 2016;45(2):262-7.
- McCormack J, Mangin D, Farrell B, Sloan J, Trimble J, Allan M, et al. Medstopper beta Vancouver: University of British Columbia; [
- Leach MJ, Pratt NL, Roughead EE. Risk of Hip Fracture in Older People Using Selective Serotonin Reuptake Inhibitors and Other Psychoactive Medicines Concurrently: A Matched Case-Control Study in Australia. Drugs Real World Outcomes. 2017;4(2):87-96.
- Hilmer SN, Mager DE, Simonsick EM, Cao Y, Ling SM, Windham BG, et al. A drug burden index to define the functional burden of medications in older people. Arch Intern Med. 2007;167(8):781-7.
- Hilmer SN. Calculating and using the drug burden index score in research and practice. Expert Rev Clin Pharmacol. 2018;11(11):1053-5.
- Kouladjian L, Gnjidic D, Chen TF, Hilmer SN. Development, validation and evaluation of an electronic pharmacological tool: The Drug Burden Index Calculator(c). Res Social Adm Pharm. 2016;12(6):865-75.
- 77. Sydney TUo, Northern Sydney Local Health District. Welcome to the Goal-directed Medication review Electronic Decision Support System (G-MEDSS©) website Sydney: The University of Sydney and Northern Sydney Local Health District.; 2024 [Available from: www.gmedss.com/about.
- 78. Fujita K, Hooper P, Masnoon N, Lo S, Gnjidic D, Etherton-Beer C, et al. Impact of a Comprehensive Intervention Bundle Including the Drug Burden Index on Deprescribing Anticholinergic and Sedative Drugs in Older Acute Inpatients: A Nonrandomised Controlled Before-and-After Pilot Study. Drugs Aging. 2023;40(7):633-42.
- Masnoon N, Lo S, Hilmer S. A stewardship program to facilitate anticholinergic and sedative medication deprescribing using the drug burden index in electronic medical records. Br J Clin Pharmacol. 2023;89(2):687-98.
- University of Sydney, Morthern Sydney Local Health District. About G-MEDSS Sydney: University of Sydney, ; 2024 [
- Liu BM, Kouladjian O'Donnell L, Redston MR, Fujita K, Thillainadesan J, Gnjidic D, et al. Association of the Drug Burden Index (DBI) exposure with outcomes: A systematic review. J Am Geriatr Soc. 2024;72(2):589-603.

- Hilmer SN, Gnjidic D. The anticholinergic burden: from research to practice. Aust Prescr. 2022;45(4):118-20.
- Liu BM, Redston MR, Fujita K, Thillainadesan J, Gnjidic D, Hilmer SN. The Impact of Deprescribing Interventions on the Drug Burden Index and Other Outcomes: A Systematic Review. J Am Med Dir Assoc. 2024;25(7):105021.
- 84. King R, Rabino S. ACB Calculator UK: King and Rabino; [
- 85. King R, Rabino S. ACB calculator 2024 [Available from: www.acbcalc.com/.
- Boustani M, Campbell N, Munger S, Maidment I, Fox C. Impact of Anticholinergics on the Aging Brain: A Review and Practical Application. Aging Health. 2008;4(3):311-20.
- Kiesel EK, Hopf YM, Drey M. An anticholinergic burden score for German prescribers: score development. BMC Geriatr. 2018;18(1):239.
- 88. de Vries M, Seppala LJ, Daams JG, van de Glind EMM, Masud T, van der Velde N, et al. Fall-Risk-Increasing Drugs: A Systematic Review and Meta-Analysis: I. Cardiovascular Drugs. J Am Med Dir Assoc. 2018;19(4):371 e1- e9.
- Seppala LJ, van de Glind EMM, Daams JG, Ploegmakers KJ, de Vries M, Wermelink A, et al. Fall-Risk-Increasing Drugs: A Systematic Review and Meta-analysis: III. Others. J Am Med Dir Assoc. 2018;19(4):372 e1- e8.
- 90. Seppala LJ, Wermelink A, de Vries M, Ploegmakers KJ, van de Glind EMM, Daams JG, et al. Fall-Risk-Increasing Drugs: A Systematic Review and Meta-Analysis: II. Psychotropics. J Am Med Dir Assoc. 2018;19(4):371 e11- e17.
- 91. Seppala LJ, Petrovic M, Ryg J, Bahat G, Topinkova E, Szczerbinska K, et al. STOPPFall (Screening Tool of Older Persons Prescriptions in older adults with high fall risk): a Delphi study by the EuGMS Task and Finish Group on Fall-Risk-Increasing Drugs. Age Ageing. 2021;50(4):1189-99.
- 92. Carefree, University of Amsterdam, ADFICE_IT, ZonMw Projecten. Choose a medication class to see the decision advice for withdrawing the medication among fallers Amsterdam: University of Amsterdam; [Available from: kik.amc.nl/falls/ decision-tree.
- 93. NSW Therapeutic Advisory Group. Medicationrelated Falls Risk Assessment Tool (MFRAT) Sydney: NSW TAG; 2020 [Available from: <u>www.nswtag.org.au/wp-content/uploads/2020/11/</u> <u>NSW-TAG-8.2_Med-related-Falls-Risk-Assessment-ToolMFRAT.pdf.</u>

- 94. NSW Therapeutic Advisory Group. Medicationrelated falls risk assessment tool (MFRAT) Sydney: NSW Therapeutic Advisory Group; 2020 [Available from: www.nswtag.org.au/wp-content/ uploads/2020/11/NSW-TAG-8.2_Med-related-Falls-Risk-Assessment-ToolMFRAT.pdf.
- 95. Pratt NL, Ramsay EN, Kalisch Ellett LM, Nguyen TA, Barratt JD, Roughead EE. Association between use of multiple psychoactive medicines and hospitalization for falls: retrospective analysis of a large healthcare claim database. Drug Saf. 2014;37(7):529-35.
- 96. Osman A, Kamkar N, Speechley M, Ali S, Montero-Odasso M. Fall risk-increasing drugs and gait performance in community-dwelling older adults: A systematic review. Ageing Res Rev. 2022;77:101599.
- 97. Prasert V, Pooput P, Ponsamran P, Vatcharavongvan P, Vongsariyavanich P. The association between falls and fall-risk-increasing drugs among older patients in out-patient clinics: A retrospective cohort, single center study. Res Social Adm Pharm. 2024.
- 98. Paar E, Lai E, Drzaic M, Kummer I, Buzancic I, Hadziabdic MO, et al. Fall risk-increasing drugs and associated health outcomes among communitydwelling older patients: A cross-sectional study in Croatian cohort of the EuroAgeism H2020 project. Acta Pharm. 2024.
- 99. Victorian Government Department of Health. Falls Risk Assessment Tool (FRAT) Victoria: Department of Health; 2024 [
- 100. Scottish Government Polypharmacy Model of Care Group. Polypharmacy Guidance, Realistic Prescribing 3rd Edition, . Edinburgh; 2018.
- 101. Scottish Government Polypharmacy Model of Care Group. Polypharmacy guidance, realistic prescribing 3rd Edition Edinburgh: Scottish Government; 2018 [Available from: www.therapeutics.scot.nhs.uk/ wp-content/uploads/2018/04/Polypharmacy-Guidance-2018.pdf.
- 102. Australian Government Department of Veterans' Affairs. Cumulative Medicines Risk Adelaide: University of South Australia; 2022 [Available from: <u>www.veteransmates.net.au/topics/complexmedicines/therapeutic-brief/</u>.
- 103. Veterans' MATES, Australian Government Department of Veterans' Affairs. Cumulative risk calculator Adelaide: Quality Use of Medicines and Pharmacy Research Centre; 2024 [Available from: <u>www.veteransmates.net.au/cumulative-riskcalculator/</u>.
- 104. South London and Maudsley NHS Foundation Trust. Medichec London: South London and Maudsley NHS Foundation Trust; [Available from: <u>www.medichec.com/</u>.

- 105. Bishara D, Harwood D, Sauer J, Taylor DM. Anticholinergic effect on cognition (AEC) of drugs commonly used in older people. Int J Geriatr Psychiatry. 2017;32(6):650-6.
- 106. South London and Maudsley NHS Foundation Trust. Assessing medication for anticholenergic buden (using the anticholenergic effect on cognition tool) and for QTc prolongation, hypronatreaemia, bleeding, dizziness, drowsiness and constipation London: NHS; 2024 [Available from: www.medichec.com/.
- 107. Lim R, Ellett LK, Roughead EE, Cheah PY, Masnoon N. Patient-Reported Questionnaires to Identify Adverse Drug Reactions: A Systematic Review. Int J Environ Res Public Health. 2021;18(22).
- 108. Schoenmakers TW, Teichert M, Wensing M, de Smet PA. Evaluation of Potentially Drug-Related Patient-Reported Common Symptoms Assessed During Clinical Medication Reviews: A Cross-Sectional Observational Study. Drug Saf. 2017;40(5):419-30.
- 109. Schoenmakers T, Wensing M, De Smet P, Teichert M. Online resource 1: PROMISE instrument 2018 [Available from: <u>pmc.ncbi.nlm.nih.gov/articles/</u> <u>instance/5840243/bin/11096_2017_575_MOESM1_</u> <u>ESM.pdf.</u>
- 110. Schoenmakers TWA, Wensing M, De Smet P, Teichert M. Patient-reported common symptoms as an assessment of interventions in medication reviews: a randomised, controlled trial. Int J Clin Pharm. 2018;40(1):126-34.
- 111. Hedström M, Lidström B, Hulter Åsberg K. PHASE-20: ett nytt instrument för skattning av möjliga läkemedelsrelaterade symptom hos äldre personer i äldreboende [PHASE-20: A new instrument for assessment of possible therapeutic drug-related symptoms among elderly in nursing homes]. . Vård i Norden, . 2009;29:9–14.
- 112. Hedstrom M, Carlsson M, Ekman A, Gillespie U, Mork C, Asberg KH. Development of the PHASE-Proxy scale for rating drug-related signs and symptoms in severe cognitive impairment. Aging Ment Health. 2018;22(1):53-60.
- 113. Hedström M. PHASE-20 in English 2016 [Available from: www.regionuppsala.se/samverkanswebben/ for-vardgivare/kunskapsstod/lakemedel/ tillgangliga-resurser-vid-lakemedelsbehandling/ apotekare-i-varden/phase-20/phase-20-english/.
- 114. Puumalainen E, Airaksinen M, Jalava SE, Chen TF, Dimitrow M. Comparison of drug-related problem risk assessment tools for older adults: a systematic review. Eur J Clin Pharmacol. 2020;76(3):337-48.

- 115. Stampfli D, Boeni F, Gerber A, Battig VAD, Weidmann R, Hersberger KE, et al. Assessing the ability of the Drug-Associated Risk Tool (DART) questionnaire to stratify hospitalised older patients according to their risk of drug-related problems: a cross-sectional validation study. BMJ Open. 2018;8(6):e021284.
- 116. Berman RL, Iris M, Conrad KJ, Robinson C. Validation of the MedUseQ: A Self-Administered Screener for Older Adults to Assess Medication Use Problems. J Pharm Pract. 2019;32(5):509-23.
- 117. Baby B, McKinnon A, Patterson K, Patel H, Sharma R, Carter C, et al. Tools to measure barriers to medication management capacity in older adults: a scoping review. BMC Geriatr. 2024;24(1):285.
- Fuller D, Watson R. Validating a self-medication risk assessment instrument. Clinical Effectiveness in Nursing. 2005;9(1):78-83.
- City of Bradford Metropolitan District Council. Bradford Medication Support Guidance Bradford; 2021.
- 120. Dimitrow M, Saarenmaa R, Airaksinen M, Hassan G, Puumalainen E, Pitrova M, et al. Medication risk checklist for older adults (LOTTA) development and validation of a self-assessment tool. Ann Med. 2023;55(2):2287707.
- 121. Criddle DT, Devine B, Murray K, Budgeon CA, Sanfilippo FM, Gupta S, et al. Developing PHarmacie-R: A bedside risk prediction tool with a medicines management focus to identify risk of hospital readmission. Res Social Adm Pharm. 2022;18(7):3137-48.
- 122. Clifford R, Criddle D, Devine B, Gupta S, Chong YL, Tan ML, et al. Developing PHarmacie-4 - A simple risk tool to identify patients at risk of medicationrelated problems post-discharge Res Social Adm Pharm. 2018;14:e23ee56.
- 123. Scott IA, Hilmer SN, Reeve E, Potter K, Le Couteur D, Rigby D, et al. Reducing inappropriate polypharmacy: the process of deprescribing. JAMA Intern Med. 2015;175(5):827-34.
- 124. Reeve E, Wiese MD, Hendrix I, Roberts MS, Shakib S. People's attitudes, beliefs, and experiences regarding polypharmacy and willingness to Deprescribe. J Am Geriatr Soc. 2013;61(9):1508-14.
- 125. Reeve E, Shakib S, Hendrix I, Roberts MS, Wiese MD. Development and validation of the patients' attitudes towards deprescribing (PATD) questionnaire. Int J Clin Pharm. 2013;35(1):51-6.
- 126. Reeve E, Low LF, Shakib S, Hilmer SN. Development and Validation of the Revised Patients' Attitudes Towards Deprescribing (rPATD) Questionnaire: Versions for Older Adults and Caregivers. Drugs Aging. 2016;33(12):913-28.
- 127. Reeve E, Anthony AC, Kouladjian O'Donnell L, Low LF, Ogle SJ, Glendenning JE, et al. Development

and pilot testing of the revised Patients' Attitudes Towards Deprescribing questionnaire for people with cognitive impairment. Australas J Ageing. 2018;37(4):E150-E4.

- 128. Reeve E, Bayliss EA, Shetterly S, Maiyani M, Gleason KS, Norton JD, et al. Willingness of older people living with dementia and mild cognitive impairment and their caregivers to have medications deprescribed. Age Ageing. 2023;52(1).
- 129. Jungo KT, Weir KR, Cateau D, Streit S. Older adults' attitudes towards deprescribing and medication changes: a longitudinal sub-study of a cluster randomised controlled trial. BMJ Open. 2024;14(1):e075325.
- 130. McCarthy C, Flood M, Clyne B, Smith SM, Boland F, Wallace E, et al. Association between patient attitudes towards deprescribing and subsequent prescription changes. Basic Clin Pharmacol Toxicol. 2023;133(6):683-90.
- 131. Turner JP, Martin P, Zhang YZ, Tannenbaum C. Patients beliefs and attitudes towards deprescribing: Can deprescribing success be predicted? Res Soc Admin Pharm. 2020;16(4):599-604.
- 132. Faculty of Pain Medicine AaNZCoA. Opioid calculator: FPM ANZCA; 2022 [Available from: <u>www.opioidcalculator.com.au/</u>.
- 133. Faculty of Pain Medicine AaNZCoA. Opioid calculator Victoria: FPMANZCA; 2022 [Available from: <u>www.opioidcalculator.com.au/</u>.
- 134. Antipsychotic switching tool [Update]. Aust Prescr. 2019;42(6):213.
- 135. Keks N, Schwartz D, Hope J. Antipsychotic switching tool. Aust Prescr. 2019;42(5):156.
- 136. McIntosh D, Procyshyn RM. SwitchRx: the online medication switching tool [Available from: <u>www.switchrx.com/</u>.
- 137. Opioid tapering calculator for health professionals: Victorian Department of Health; 2022 [Available from: www.health.vic.gov.au/publications/opioidtapering-calculator.
- 138. West of Scotland Chronic Pain Education Group. Pain Management: CPEG; 2024 [Available from: www.paindata.org/index.php.
- 139. West of Scotland Chronic Pain Education Group. Taper calculator 2024 [Available from: <u>www.paindata.org/taper.php</u>.
- 140. West of Scotland Chronic Pain Education Group. Guidance on opioid switching 2024 [Available from: www.paindata.org/calculator.php.

Appendix 1: Australian Potentially Inappropriate Medicines List⁵⁶

PIM ¹ or medicine class group	Avoid these drugs in older people	Avoid this medicine or medicine class in older people with these conditions	Instead of prescribing this medicine or class of medicines for older people, consider these alternatives
Alpha-adrenoreceptor antagonists (prazosin)	• Prazosin	 Risk of hypotension Taking other antihypertensive medications Frailty Risk of falls Initial dose adverse effects 	 ACE inhibitors (e.g. enalapril and lisinopril) Angiotensin Il receptor blockers (e.g. candesartan and irbesartan) Calcium channel blockers (e.g. amlodipine and diltiazem) Silodosin Tamsulosin
Antiemetics – dopamine antagonist (chlorpromazine, domperidone, metoclopramide and prochlorperazine)	ChlorpromazineProchlorperazine	 Parkinson disease Polypharmacy Lewy body dementia Neurodegenerative diseases (e.g. Alzheimer disease and cognitive impairment) Frailty High risk of falls 	OndansetronDomperidone
Antihypertensives, centrally acting (methyldopa, clonidine and moxonidine)	• Methyldopa	 Risk of hypotension Risk of falls Taking other antihypertensive medications Frailty 	 ACE inhibitors (e.g. enalapril and lisinopril) Angiotensin Il receptor blockers (e.g. candesartan and irbesartan) Thiazide diuretics (e.g. hydrochlorothiazide)
Antipsychotics (haloperidol, zuclopenthixol, trifluoperazine, thioridazine, periciazine and flupenthixol)	 Haloperidol Zuclopenthixol Trifluoperazine Thioridazine Periciazine Flupenthixol 	 At risk of extrapyramidal reactions Taking anticholinergic medications Polypharmacy Frailty Neurodegenerative diseases (e.g. delirium) Cognitive impairment Cardiovascular diseases Cerebrovascular diseases Risk of falls 	 Atypical antipsychotics (e.g. quetiapine) Risperidone Nonpharmacological strategies (e.g. yoga)

PIM ¹ or medicine class group	Avoid these drugs in older people	Avoid this medicine or medicine class in older people with these conditions	Instead of prescribing this medicine or class of medicines for older people, consider these alternatives
Antipsychotics (olanzapine, quetiapine, amisulpride, ziprasidone, lurasidone, risperidone, aripiprazole and paliperidone)	• Olanzapine	 Cardiometabolic syndrome (e.g. high blood pressure, high blood sugar) Risk of falls Polypharmacy When a nonpharmacological method has not been tried adequately Neurodegenerative diseases (e.g. delirium) Long-term use 	QuetiapineRisperidone
Benzodiazepine, long- acting (clobazam, clonazepam, diazepam, flunitrazepam and nitrazepam)	ClonazepamFlunitrazepam	 Dependence Other medications with sedative properties Polypharmacy Frailty Neurodegenerative diseases (e.g. delirium) Cognitive impairment Poor renal function Long-term use Risk of falls 	 Short-acting benzodiazepine (e.g. oxazepam) Melatonin (for indication of sleep) Nonpharmacological strategies (e.g. yoga)
Benzodiazepines, medium- acting (bromazepam and lorazepam)	BromazepamLorazepam	 Falls With other medications with sedative properties Polypharmacy Frailty, Neurodegenerative diseases (e.g. delirium) Cognitive impairment 	 Short-acting benzodiazepine Melatonin (for indication of sleep) Nonpharmacological strategies (e.g. yoga)
Benzodiazepines, short- acting (alprazolam, oxazepam and temazepam)	• Alprazolam	 Falls With other medications with sedative properties Polypharmacy Frailty Neurodegenerative diseases (e.g. delirium) Dependency Renal impairment Long-term use 	 Oxazepam Temazepam Melatonin (for indication of sleep) Nonpharmacological strategies (e.g. yoga)



PIM ¹ or medicine class group	Avoid these drugs in older people	Avoid this medicine or medicine class in older people with these conditions	Instead of prescribing this medicine or class of medicines for older people, consider these alternatives
Genito-urinary anticholinergics (oxybutynin, propantheline, tolterodine and solifenacin)	• Oxybutynin	 With other anticholinergics Frailty Polypharmacy Risk of falls Neurodegenerative diseases (e.g. delirium) Constipation Cognitive impairment 	N/A
NSAIDs, nonselective (indomethacin, diclofenac, ketorolac, piroxicam, meloxicam, ibuprofen, naproxen, ketoprofen and mefenamic acid)	 Diclofenac Indomethacin Ibuprofen Ketoprofen Piroxicam Meloxicam Ketorolac 	 History of gastrointestinal bleeding Increased bleeding risks Frailty Poor renal function Peptic ulcer disease Multimorbidity Chronic kidney disease Heart failure Cardiovascular diseases 	Paracetamol
NSAIDs, selective (celecoxib and etoricoxib)	N/A	 History of gastrointestinal bleeding Increased bleeding risks Frailty Poor renal function Heart failure Cardiovascular disease Chronic kidney disease Long-term use Taking ACE inhibitors or diuretics 	 Paracetamol Celecoxib
Opioids (morphine, pethidine, fentanyl, dextropropoxyphene, hydromorphone, buprenorphine, oxycodone and codeine)	 Pethidine Fentanyl Codeine Hydromorphone Dextropropoxyphene 	 Polypharmacy Risk of falls Frailty Poor renal function Neurodegenerative diseases (e.g. delirium) Constipation Opioid dependency Long-term use Impaired cognition Chronic pain 	PhysiotherapyParacetamolOxycodoneBuprenorphine



PIM ¹ or medicine class group	Avoid these drugs in older people	Avoid this medicine or medicine class in older people with these conditions	Instead of prescribing this medicine or class of medicines for older people, consider these alternatives
Oral anticoagulants – direct thrombin inhibitors (dabigatran)	• Dabigatran	 Increased risk of bleeding Multimorbidity Peptic ulcer disease Frailty Risk of falls Poor blood pressure control Chronic kidney disease Poor renal function 	N/A
Oral anticoagulants – Factor Xa inhibitors (apixaban and rivaroxaban)	• Rivaroxaban	 Peptic ulcer disease Increased bleeding risk Risk of falls Multimorbidity Polypharmacy Poor renal function Chronic kidney disease 	N/A
Sedating antihistamines (diphenhydramine, doxylamine, dexchlorpheniramine, pheniramine, promethazine, cyclizine, chlorpheniramine and cyproheptadine)	Promethazine	 Taking other medications with sedative properties Cognitive impairment Taking anticholinergics Frailty Neurodegenerative diseases (e.g. delirium) Risk of falls Polypharmacy 	• Nonsedating antihistamines (e.g. fexofenadine)
Sulfonylureas (glibenclamide, glipizide, gliclazide and glimepiride)	GlibenclamideGlimepiride	 With other glucose-lowering medications High risk of falls Frailty Chronic kidney diseases Polypharmacy Multimobidity Renal impairment Irregular diet Dehydration 	 Metformin Gliclazide Dipeptidyl peptidase-4 inhibitors (sitagliptin and saxagliptin) Sodium-glucose transport protein 2 inhibitor (dapagliflozin)



PIM ¹ or medicine class group	Avoid these drugs in older people	Avoid this medicine or medicine class in older people with these conditions	Instead of prescribing this medicine or class of medicines for older people, consider these alternatives
Tramadol	N/A	 Multimorbidity Frailty Neurodegenerative diseases (e.g. delirium) Risk of falls Polypharmacy Poor renal function Cognitive impairment Long-term use Taking antidepressant medications Epilepsy Risk of seizures 	 Paracetamol NSAIDs
Tricyclic antidepressants (imipramine, clomipramine, amitriptyline, nortriptyline, doxepin and dosulepin [dothiepin])	 Doxepin Dosulepin (dothiepin) 	 With other anticholinergics Frailty Polypharmacy Risk of falls Neurodegenerative diseases (e.g. delirium) Constipation Cognitive impairment With other medications with sedative properties Risk of postural hypotension Benign prostatic hyperplasia 	 Selective serotonin reuptake inhibitors (e.g. citalopram and paroxetine) Serotonin and norepinephrine reuptake inhibitors (e.g. duloxetine) Mirtazapine
Z-drugs (zolpidem and zopiclone)	N/A	 Dependency Taking other medications with sedative properties Frailty Neurodegenerative diseases (e.g. delirium) Risk of falls Polypharmacy Cognitive impairment Long-term use 	 Melatonin Nonpharmacological strategies (e.g. sleep hygiene)

Abbreviations: ACE, angiotensin-converting enzyme; N/A, not applicable; NSAID, nonsteroidal anti-inflammatory drug; PIM, potentially inappropriate medicine.

Source

the Australian Potentially Inappropriate Medicines List⁵⁶. Created by Wang KN, Etherton-Beer CD, Sanfilippo F, Page AT. Available under CC BY-NC 4.0.³⁰ at: <u>www.onlinelibrary.wiley.com/doi/10.1111/imj.16322</u>





Quality Use of Medicines and Pharmacy Research Centre University of South Australia GPO Box 2471 Adelaide SA 5001 www.unisa.edu.au